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F’-pocket of CD1d
Joren Guillaume1, Jing Wang2, Jonas Janssens1, Soumya G. Remesh2, Martijn D. P. Risseeuw1, 
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Invariant Natural Killer T-cells (iNKT-cells) are an attractive target for immune response modulation, 
as upon CD1d-mediated stimulation with KRN7000, a synthetic α-galactosylceramide, they 
produce a vast amount of cytokines. Here we present a synthesis that allows swift modification of 
the phytosphingosine side chain by amidation of an advanced methyl ester precursor. The resulting 
KRN7000 derivatives, termed α-galactosylsphingamides, were evaluated for their capacity to stimulate 
iNKT-cells. While introduction of the amide-motif in the phytosphingosine chain is tolerated for CD1d 
binding and TCR recognition, the studied α-galactosylsphingamides showed compromised antigenic 
properties.
Invariant natural killer T-cells (iNKT-cells) are a small set of glycolipid reactive T-cells that bridge innate and 
adaptive immunity. They display characteristics of both the NK cell lineage (mouse NK1.1, human CD161) and 
conventional thymus-derived T-cells1. Their semi-invariant T-cell receptor (TCR) is composed of an invariant 
Vα14-Jα18 chain in mice (homologous Vα24-Jα18 chain in humans), preferentially paired with Vβ8.2, Vβ7 
or Vβ2 (Vβ11 in humans). Whereas conventional T-cells are activated by peptide antigens presented by MHC 
proteins, iNKT-cells typically recognize glycolipid antigens presented by MHC class 1 like CD1d molecules on 
antigen presenting cells2.
The prototypical antigen for iNKT-cell stimulation is KRN7000, also known as α-GalCer (1), a synthetic gly-
colipid derived from agelasphins found in marine sponge extracts (Fig. 1)3, 4. Structural data illustrated that the 
lipid chains of α-GalCer are bound in two hydrophobic pockets deeply buried in CD1d5, 6. The larger A’-pocket 
binds the fatty acid part while the linear F’-pocket accommodates the phytosphingosine chain. Consequently, the 
galactose sugar is positioned at the surface of the CD1d binding groove and is available for recognition by the 
TCR of iNKT-cells7.
Upon stimulation, iNKT-cells rapidly secrete large amounts of pro-inflammatory Th1- (e.g., IFN-γ) and 
anti-inflammatory Th2-cytokines (e.g., IL-4). These cytokines mediate immune responses against tumors8, 
microbial infections1, 9 and auto-immunity10. In addition, iNKT-cells transactivate other immune cells includ-
ing dendritic cells, B- and T-cells, macrophages and NK-cells and are thus able to orchestrate complex immune 
functions1. Despite the potent immune response triggered by α-GalCer, this antigen showed limited therapeutic 
efficacy in several clinical studies11. The lack of therapeutic effect is attributed to the antagonizing activities of the 
secreted pro-inflammatory Th1- and anti-inflammatory Th2-cytokines. Accordingly, the search for improved 
α-GalCer analogues capable of inducing a biased cytokine release is ongoing.
To date, the growing library of α-GalCer analogues mainly consists of glycolipids with an altered fatty acid 
chain12, 13 and/or carbohydrate part14–17. In addition, a vast amount of non-glycosidic analogues, including 
C-glycosides18–20 and cyclitol derivatives21 exist. However, analogues with modifications in the phytosphingosine 
chain remain relatively scarce, due to the more challenging syntheses required to access these analogs.
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A common strategy for the synthesis of α-GalCer analogues modified in the phytosphingosine moiety relies 
on the Wittig olefination on L-Garner’s aldehyde, followed by stereoselective dihydroxylation of the Z-double 
bond furnishing the required d-ribo stereochemistry14, 22. Although this approach may afford high stereoselec-
tivity, it inevitably leads to minor unwanted isomers thereby lowering the overall yield and forcing demanding 
purification steps ahead in the synthesis.
Hitherto, a small number of phytosphingosine modified analogues have been reported, some of which exhibit 
interesting biological properties. Most notably, OCH (2), a glycolipid with a truncated phytosphingosine chain 
and a slightly trimmed fatty acid residue, became a prototypical Th2-polarizing iNKT-cell ligand23, 24. Wong and 
coworkers reported derivatives with a terminal phenyl group in the sphingosine chain (3)25. Interestingly, the 
immunological properties of these analogues were strongly dependent on the relative position of the aromatic 
ring12, 22, 26. More recently, Park et al. demonstrated that selected derivatives bearing a pyrazole moiety in the 
phytosphingosine chain (4) give rise to a Th2-biased cytokine profile27, 28. These examples demonstrate that alter-
ations of the sphingosine chain are tolerated and may afford analogues with interesting cytokine profiles.
Up to now, the mechanism of cytokine polarization is poorly understood, although there is ample of evidence 
suggesting that the stability of the CD1d/glycolipid/TCR-complex is an important contributing factor29. The 
potent Th1-response observed for α-GalCer derivatives featuring aromatic moieties in the acyl chain, is attrib-
uted to the formation of additional Van der Waals interactions with amino acid residues lining the A’-pocket30. 
Consequently these glycolipids exhibit an enhanced affinity for CD1d resulting in the observed cytokine bias. In 
analogy, the potent Th1-polarizing sugar-modified galactosylceramides previously synthesized in our lab, also 
feature a greater CD1d-affinity due to the formation of an extra binding pocket in CD1d via induced-fit31.
A study by McCarthy et al. indicates that although both the acyl chain and phytosphingosine contribute to 
the stability of the glycolipid/CD1d-complex, it is the phytosphingosine chain that controls TCR-binding and 
iNKT-cell activation, since ligand-induced conformational changes of the F’-pocket allosterically influence the 
CD1d/glycolipid footprint32. The aforementioned arguments excited us to explore a synthetic strategy for the 
preparation of phytosphingosine modified α-GalCer analogues, allowing us to introduce variations in the later 
stages of the synthesis via amide coupling. Molecular modeling studies indicate that the amide moiety, when 
placed at the right position, can potentially form a hydrogen bond with Tyr73 in the CD1d-binding groove and 
may consequently enhance the glycolipid/CD1d-complex stability (Fig. 2). The selected amide substituents are 
aimed at reinforcing the interactions (e.g., by π-π-stacking) with aromatic residues lining the F’-pocket.
To ensure acceptable solubility of the envisioned analogues, we opted to equip these initially with an octanoyl 
moiety, which was shown to retain most of the antigenic properties when replacing the N-hexacosanoyl group of 
α-GalCer33.
Results and Discussion
Chemistry. An overview of the synthesized α-galactosylsphingamides is shown in Table 1.
As shown in the retrosynthetic analysis (Fig. 3), the α-galactosylsphingamides (5a-h, 6–9d and 9f) can be 
accessed from methyl ester 10, which is obtained through Lewis acid catalyzed glycosylation of glycosyl acceptor 
12. The latter would be obtained by conversion of alcohol 13 to an azide with an inversion of stereochemistry at 
the carbon centre, followed by selective benzyl ether cleavage to afford the primary alcohol. The 2-deoxygalactose 
intermediate 14, prepared from commercially available tri-O-acetyl-d-galactal (16), would serve as a substrate for 
a Wittig olefination with phosphonium ylid 15.
The synthetic route towards glycosyl acceptor 12 is outlined in Fig. 4. It was decided to start from commer-
cially available tri-O-acetyl-d-galactal (16), which was readily converted into the 3,4,6-tri-O-benzyl-protected 
derivative 1734. Hydrolysis of the enol ether was achieved upon treatment with 4 m sulfuric acid, furnishing 
2-deoxygalactose intermediate 1435. Next, the Wittig reaction on 14 with methyl(triphenylphosphoranylidene)
Figure 1. Structures of α-GalCer (1) and OCH (2) and known phytosphingosine-modified α-GalCer 
derivatives 3 and 4.
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acetate was investigated. When the reaction was carried out in THF, α,β-unsaturated ester 18 was obtained 
exclusively as the E-isomer in moderate yield (64%). Performing the reaction in refluxing toluene increased the 
yield to 79%, while also providing solely the E-isomer. To avoid Michael type side reactions and to eliminate the 
possibility for a 1,3-dipolar cycloaddition upon introduction of the azide, saturation of the double bond was 
Figure 2. Model of the binding of 5a to mouse CD1d. The 5a carbons are depicted in green, while the Tyr73.A 
carbons are colored in yellow. The possible hydrogen bond with the amide oxygen atom is highlighted. Ribbons 
are colored as skyblue for the CD1d (chain A) and the mouse NKT TCR chains are colored in grey.
R1
R1 = C7H15 R1 = C11H23 R1 = C15H31 R1 = C19H39 R1 = C25H51R2
C9H19 5a
 (CH2)2Ph 5b
 (CH2)4Ph 5c
 (CH2)6Ph 5d 6d 7d 8d 9d
 (CH2)8Ph 5e
Ph-m-C5H11 5f 9f
Ph-p-C5H11 5g
((CH2)2O)2C2H5 5h
Table 1. Overview of the synthesized α-galactosylsphingamides.
Figure 3. Retrosynthesis of the target α-galactosylsphingamides.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 4276  | DOI:10.1038/s41598-017-04461-7
accomplished by conjugate reduction with nickel(II) chloride and sodium borohydride. Mitsunobu reaction with 
diphenyl phosphoryl azide (DPPA) converts the C2-OH to an azido group with the appropriate stereochemistry 
(19). Next, selective deprotection of the primary hydroxyl was achieved by treatment of 19 with zinc chloride in 
acetic anhydride followed by Zemplén deacetylation of the intermediate acetate to furnish acceptor 12.
Next, TMSOTf-promoted glycosylation of acceptor 12 with galactosyl trichloroacetimidate 1136 afforded 
α-galactoside 10 in good yield and without notable formation of the β-glycoside. The ability to diversify the 
methyl ester after glycosylation is convenient as it reduces the number of linear steps towards the target α-GalCer 
analogues. A Lewis acid-catalyzed amidation with the appropriate amines gave intermediates 20a-h. Next, the 
azido group was subjected to Staudinger reduction with trimethylphosphine and the resulting amine was coupled 
with octanoic acid using EDC. Finally, catalytic hydrogenolysis afforded the desired compounds 5a-h. Analogues 
6-9d and 9f with alternative acyl moieties were synthesized according to similar procedures.
Biological evaluation. To assess the biological activity of the α-galactosylsphingamides, we analyzed the 
IFN-γ- and IL-4-levels after intraperitoneal injection of 5 µg of the galactosylsphingamides 5a-h in mice (Fig. 5).
The marginal cytokine release induced by this series indicates that the introduction of an amide moiety in the 
phytosphingosine chain compromises the antigenic potency.
In an effort to explain the poor antigenicity of 5a-h, we next tested the binding of the Vα14Vβ8.2 TCR of the 
murine iNKT-cell hybridoma 2C12 to mCD1d-presenting ligands 5d,e using surface plasmon resonance (SPR) 
and compared it with the binding of PBS-2533, an α-GalCer analogue that also features an octanoic acid residue. 
It should be noted that in our hands, PBS-25 was inactive in the in vivo cytokine secretion assay (Supporting 
Figure S1). To further evaluate whether the low antigenicity of 5d is resulting from the amide functionality 
in the phytosphingosine chain, we synthesized glycolipid 23 (Fig. 6), which is the amide-deleted counterpart 
of α-galactosphingamides 5d and 5e. Surprisingly, all ligands were bound with similarly high TCR affinities 
(KD = 38–50 nM) (Fig. 7). Therefore, the TCR binding kinetics cannot explain the inability of the galactosyl-
sphingamides to induce robust cytokine production in vivo. In addition, the maximal response (RU 120–220) 
observed for the individual sensorgrams of the α-galactosylsphingamides are comparable between the individual 
CD1d-ligand complexes, which were immobilized at similar levels, suggesting a similar CD1d ligand binding 
efficiency in vitro.
Figure 4. Reagents and conditions: (a) (i) Et3N, H2O, MeOH, RT, 4d; (ii) NaH, BnBr, DMF, RT, overnight, 94% 
(over 2 steps); (b) 4 m H2SO4, DMF, 0 °C → RT, overnight, 85%; (c) methyl (triphenylphosphoranylidene)acetate, 
toluene, 85 °C, 6 h, 79%; (d) NiCl2∙6 H2O, NaBH4, MeOH/THF, 0 °C, 1 h, 94%; (e) PPh3, diethylazodicarboxylate, 
diphenylphosphorylazide, THF, −20 °C → RT, 7 h, 95%; (f) (i) ZnCl2, AcOH/Ac2O, 3.5 h, RT; (ii) MeOH, 
NaOMe, pH 10, RT, overnight, 67% over 2 steps; (g) TMSOTf, THF, −30 °C, 2 h, 67%; (h) AlMe3, amine, 
CH2Cl2, reflux, overnight, 56%-85%; (i) (i) PMe3, H2O, THF, RT, 7 h; (ii) EDC, octanoic acid, CH2Cl2, RT, 
overnight, 51%–69% over 2 steps; (j) H2, Pd black, MeOH, CHCl3, RT, overnight, 37%–58%.
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Since the current galactosylsphingamides are based on a C8 fatty acid, the short acyl chain will not fully 
occupy the A’ pocket of CD1d. Likely similar to PBS-2537, free fatty acid will be recruited to fill the remainder 
of the pocket. To assess whether these spacer lipids can potentially influence the ligand potency, we synthesized 
ligands based on 5d that contained longer acyl chains of 12, 16, 20, and 26 carbon atoms (6d-9d). Since the acyl 
chain is introduced at the final stages of the synthesis, the elongated fatty acid chains could easily be introduced, 
demonstrating the versatility of our synthetic approach. We next analyzed antigenicity by measuring IFN-γ- 
and IL-4-levels after intraperitoneal injection of 5 µg of the acyl-elongated galactosylsphingamides 6-9d in mice 
(Fig. 8). Surprisingly, cytokine levels are still inferior to those observed for α-GalCer but increase slightly upon 
elongating the acyl chain. Overall, the introduction of an amide functionality in the phytosphingosine chain 
appears to result in poor iNKT-cell stimulation. The recruitment of spacer lipids occupying the A’ pocket was 
observed for 5a-d, but the spacer lipid had no impact on the antigenic potency of the galactosylsphingamides 
since the antigenic potency of 8d and 9d, which have no space to fit a spacer lipid, also perform poorly.
Structural data. To gain insights into the poor antigenic potency of the glycolipids but high affinity TCR 
binding, we determined the crystal structure of the CD1d/5d-complex as well as that of the complex of CD1d 
with compound 23, which resembles 5d but lacks the amide group. As expected, 23 gives rise to well-defined elec-
tron density and is rigidly presented using the conserved H-bond network involving CD1d-residues Asp80 and 
the 3’- and 4’-OH of phytosphingosine, as well as CD1d Thr156 and the glycosidic oxygen, and most importantly, 
CD1d-residue Asp153 and the 2”-, and 3”-OH of the galactose (Fig. 9A–D). Surprisingly, galactosylsphingamide 
5d is presented less well ordered by CD1d, as judged by the less contoured electron density (Fig. 9A,B). This 
slight disorder of the galactose presentation correlates well with the increase in the H-bond distance between 
CD1d and 5d. Especially the 2”-OH interaction with CD1d Asp153 is increased compared to 23 (3.0 vs. 2.6 Å, 
Fig. 9C,D), while the 3’-OH of phytosphingosine is also less intimately contacted by CD1d Asp80 (3.1 vs. 2.5 Å). 
Notewhorthy, the computationally modelled hydrogen bond between the amide oxygen and Tyr73 was not 
observed in the glycolipid/CD1d crystal structure. When looking down into the binding groove of CD1d (TCR 
view), we noticed lack of the F’-roof closure by 5d, while 23 induced the F’-roof formation (Fig. 9E,F). This is 
likely the result of the amide group perturbing the hydrophobic nature of the F’-pocket in general. Based on our 
previous work on microbial glycolipids, we postulated that the TCR-dissociation rate is increased for glycolipids 
that do not close the F’-roof before TCR-binding38. However, since we have not observed any differences in the 
binding kinetics, especially the dissociation rate, we speculate that a compensatory mechanism will stabilize the 
TCR-interaction and this could likely be driven by the amide group and a novel interaction within the F’-pocket 
of CD1d. This will have to be investigated in the future using TCR-co-crystal structures.
Figure 5. IL-4 and IFN-γ secretion, measured at respectively 4 h and 16 h, after intraperitoneal injection of 5 µg 
of the glycolipids in mice. Data for one individual experiment using 8 mice for each glycolipid.
Figure 6. Structures of reference compounds PBS-25 (22) and 23.
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We next compared the precise presentation of both ligand headgroups by CD1d. As suggested by the changes 
in hydrogen bond distances, the galactose of 5d is slightly elevated compared to 23, correlating with the increased 
distance in H-bonding interactions with CD1d (Fig. 10).
This slightly flexible presentation of 5d is reminiscent to the presentation of the microbial glycosphingolipid 
GalA-GSL, which was also slightly shifted in the binding groove of CD1d compared to 22 but had comparable 
TCR association rates39. Therefore, the fine presentation of the galactose is likely not the reason for the biological 
inactivity of these galactosylsphingamides.
Since the only difference between both glycolipids is the presence (5d) or absence (23) of the amide group, this 
indicates that the amide is indeed responsible for the slight elevation of the galactose but more importantly for 
Figure 7. Real-time TCR-binding kinetics to mCD1d-presented ligands. Each curve represents the TCR 
binding sensorgram to CD1d-glycolipid complexes at a different TCR concentration after reference substraction 
(binding response to CD1d without added glycolipid). Sensorgrams (top) indicate similar lipid loading levels 
for 5d-e. Single cycle TCR kinetics were measured for PBS-25 and 23. Here, TCR with increasing concentrations 
(3-fold) was sequentially added to CD1d-glycolipid with a final dissociation step of 10 min. Colored curves 
represent actual binding responses and black curves the fitted data. Kinetic values derived from the sensorgrams 
are listed below.
Figure 8. IFN-γ and IL-4 secretion, measured at 16 h and 4 h respectively, after intraperitoneal injection of 5 µg 
of the glycolipids in mice. Data for one individual experiment using 8 mice for each glycolipid.
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 4276  | DOI:10.1038/s41598-017-04461-7
the failure in closure of the F’ roof in the binary complex, the latter of which is likely the main reason for the low 
antigenicity of the α-galactosylsphingamides (Fig. 10).
Conclusion
In summary, a series of α-GalCer analogues featuring an amide bond in the phytosphingosine were synthe-
sized. The presented synthesis allows to alter an advanced methyl ester precursor after glycosylation, thereby 
reducing the number of linear steps towards the aimed α-GalCer analogues. Furthermore, the ability to 
diversify the acyl moiety in the penultimate step of the synthesis adds to the versatility of the presented 
synthesis route. Also, methyl ester 10 is an interesting intermediate for alternative derivatization of the 
phytosphingosine chain.
Biological evaluation revealed that the novel α-galactosylsphingamides are weak iNKT-cell antigens and that 
the main compromising factor is the implemented amide functionality. While extending the acyl chain offered 
partial restoration of the antigenic effect, overall iNKT-cell stimulation remained poor.
Crystal structure analysis revealed a slightly flexible presentation of the α-galactosylsphingamides to CD1d, 
where the sugar head group is slightly shifted in the CD1d binding groove. A similar binding has been observed 
for the microbial glycosphingolipid GalA-GSL, but never for known α-GalCer analogues39. These crystal struc-
tures support the hypothesis that although both the acyl chain and phytosphingosine contribute to the stability of 
the CD1d/glycolipid complex, it is the phytosphingosine chain that controls the CD1d/glycolipid footprint. How 
the amide group affects the biological activity of these compounds and how its presence compensates for the lack 
of the pre-formed F’ roof formation upon TCR binding is currently unknown and will have to be characterized by 
determining CD1d-galactosylsphingamide-TCR structures.
Figure 9. (A,B) Electron density map of 5d and 23 with CD1d. Spacer lipid (palmitic acid) is depicted in 
orange. (C,D) H-bond interactions between 5d and 23 (yellow) with CD1d (grey). (E,F) Glycolipid ligand 
presentation shown in “TCR view” from top with molecular surface of CD1d in grey and ligands as yellow 
sticks.
Figure 10. Comparison between 5d (green) and 23 (grey)presented by CD1d.
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Experimental part. General. Precoated Macherey-Nagel SIL G/UV254 plates were used for TLC, and 
spots were examined under UV light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray or by 
spraying with a solution of (NH4)6Mo7O24∙4 H2O (25 g/L) and (NH4)4Ce(SO4)4∙2 H2O (10 g/L) in H2SO4 (10%) 
followed by charring. Column chromatography was performed on Biosolve silica gel (32–63 µm, 60 Å). NMR 
spectra were obtained with a Varian Mercury 300 Spectrometer. Chemical shifts are given in ppm (δ) relative to 
the residual solvent signals, in the case of CDCl3: δ = 7.26 ppm for 1H and δ = 77.4 ppm for 13C and in the case of 
pyridine-d5: δ = 8.74, 7.58 and 7.22 ppm for 1H and δ = 149.9, 135.5 and 123.5 ppm for 13C. Exact mass measure-
ments were performed on a Waters LCT Premier XE TOF equipped with an electrospray ionization interface and 
coupled to a Waters Alliance HPLC system. Samples were infused in a in a CH3CN/HCOOH (1000:1) mixture 
at 100 µL/min.
3,4,6-Tri-O-benzyl-D-galactal (17). 3,4,6-Tri-O-acetyl-d-galactal (22.05 g, 81 mmol) was dissolved in MeOH 
(250 mL), Et3N (67 mL) and H2O (8 mL) and the reaction mixture was stirred for 5 days at room temperature. 
After completion of the reaction the solvent was removed under reduced pressure. The crude product was dried 
by making azeotropic mixture with toluene to afford pure d-galactal in quantitative yield. This material was dis-
solved in dry DMF (250 mL) and cooled to 0 °C. Sodium hydride (60% dispersion, 13 g, 324 mmol) was added 
portionwise over a period of 15 min. After 30 minutes benzyl bromide (38.8 mL, 324 mmol) was added dropwise 
and the reaction mixture was stirred overnight, allowing the temperature to rise to room temperature. Upon 
completion of the reaction, the reaction mixture was quenched with MeOH at 0 °C. The mixture was extracted 
with EtOAc (4 × 200 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 
and the solvents were evaporated under reduced pressure. The crude was purified by silica gel chromatography 
(hexane/EtOAc: 9/1) furnishing 3,4,6-tri-O-benzyl-d-galactal (31.67 g, 94%) as a white solid.
1H-NMR (300 MHz, CDCl3): δ 3.65 (dd, J = 10.1 and 5.1 Hz, 1 H, Ha-6) 3.78 (dd, J = 10.1 and 7.2 Hz, 1 H, 
Hb-6) 3.92–3.96 (m, 1 H, H-4) 4.15–4.21 (m, 2 H, H-3 and H-5) 4.41 (d, J = 12.2, 1 H, CH2Ph) 4.50 (d, J = 12.2, 
1 H, CH2Ph) 4.57–4.68 (m, 3 H, H-2, CH2Ph) 4.82–4.90 (m, 2 H, H-2, CH2Ph) 6.36 (d, J = 6.4 Hz, 1 H, H-1) 7.24–
7.36 (m, 15 H, arom. H).
13C-NMR (75 MHz, CDCl3): δ 68.38, 70.70, 70.82, 71.21, 73.26, 73.35, 75.63, 99.90, 127.37, 127.48, 127.62, 
127.83, 128.08, 128.24, 128.32, 137.94, 138.30, 138.44, 144.12.
Exact mass (ESI-MS) for C27H28NaO4 [M + Na]+ found, 439.1878; calcd, 439.1880.
2-Deoxy-3,4,6-tri-O-benzyl-D-galactose (14). To a solution of 3,4,6-tri-O-benzyl-d-galactal (31.7 g, 76 mmol) in 
DMF (250 mL) maintained at 0 °C, H2SO4 (80 mL, 4.0 M) was added dropwise. The reaction mixture was allowed 
to rise to room temperature and was stirred for 16 h. Upon completion of the reaction, the mixture was neutral-
ized with NaHCO3 (400 mL, sat. aq.) and extracted with Et2O (3 × 200 mL). The combined organic layers were 
washed with brine, dried over MgSO4, filtered and evaporated. The crude residue was purified by silica gel chro-
matography (hexane/EtOAc: 85/15) furnishing 14 (28.13 g, 85%) as a white solid.
1H-NMR (α-anomer) (300 MHz, CDCl3): δ 1.90–2.09 (m, 1 H, Ha-2) 2.23 (td, J = 12.4, 3.6 Hz, 1 H, Hb-2) 
3.41–3.73 (m, 2 H, CH2-6) 3.73–3.92 (m, 1 H, H-5) 4.00 (ddd, J = 12.0, 4.6 and 2.5 Hz, 1 H, H-3) 4.14 (t, J = 6.5 Hz, 
1 H, H-4) 4.44 (d, J = 12.0 Hz, 1 H, CH2Ph) 4.52 (d, J = 12.0 Hz, 1 H, CH2Ph) 4.59–4.66 (m, 3 H, CH2Ph) 4.94 (d, 
J = 11.8 Hz, 1 H, CH2Ph) 5.47 (d, J = 3.1 Hz, 1 H, H-1) 7.20–7.43 (m, 15 H, arom. H).
13C-NMR (75 MHz, CDCl3): δ 30.92, 34.24, 69.0, 69.79, 70.08, 70.31, 71.65, 72.97, 73.29, 73.99, 74.19, 92.39, 
94.54, 127.16, 127.40, 127.44, 127.53, 127.61, 128.02, 128.08, 128.22, 128.27, 137.67, 138.36, 138.45.
Exact mass (ESI-MS) for C27H30NaO5 [M + Na]+ found, 457.1987; calcd, 457.1985.
Data consistent with literature40.
(5R,6S,7R,E)-methyl 5,6,8- tri-O-benzyl-7-hydroxyoct-2-enoate (18). 2-Deoxy-3,4,6-tri-O-benzyl-d-galactose 
14 (3.7 g, 8.52 mmol) and methyl(triphenylphosphoranylidene)acetate (5.68 g, 17.04 mmol) were dissolved in 
anhydrous toluene (150 mL) and stirred for 6 h at 85 °C. The reaction mixture was evaporated under reduced 
pressure, and the residue was purified by silica gel chromatography (hexane/EtOAc: 8/2) to give 18 (3.29 g, 79%) 
as a slightly yellow oil.
1H-NMR (300 MHz, CDCl3): δ 2.58 (ddd, J = 7.2, 5.7 and 1.3 Hz, 2 H, H-4) 3.48–3.60 (m, 2 H, H-8) 3.62–3.70 
(m, 1 H, H-6) 3.73 (s, 3 H, OCH3) 3.76–3.84 (m, 1 H, H-5) 3.96–4.05 (m, 1 H, H-7) 4.49–4.52 (m, 2 H, CH2Ph) 
4.55–4.57 (m, 3 H, CH2Ph) 4.67 (d, J = 11.4 Hz, 1 H, CH2Ph) 5.88 (dt, J = 15.7 and 1.3 Hz, 1 H, H-2) 7.01 (dt, 
J = 15.7 and 7.4 Hz, 1 H, H-3) 7.23–7.40 (m, 15 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 33.81, 51.44, 69.66, 71.08, 72.56, 73.44, 74.06,78.48, 79.00, 123.21, 127.77, 127.86, 
127.90, 127.94, 127.99, 128.07, 128.42, 128.45, 137.68, 137.75, 137.87, 145.57, 166.64.
Exact mass (ESI-MS) for C30H35O6 [M + H]+ found, 491.2427; Calcd., 491.2428.
(5R,6S,7R)-methyl 5,6,8- tri-O-benzyl -7-hydroxyoctanoate (13). NiCl2.6 H2O (800 mg, 3.36 mmol) and NaBH4 
(508 mg, 13.42 mmol) were added to a stirred solution of unsaturated ester 18 (3.29 g, 6.71 mmol) in MeOH 
(37 mL) and THF (3.7 mL) at 0 °C. After 1 h, the reaction mixture was filtered through Celite and the filter cake 
rinsed with Et2O. Evaporation of the filtrate yielded 13 (3.09 g, 94% yield) as a yellow oil which could be used in 
the next step without further purification.
1H-NMR (300 MHz CDCl3) δ 1.52–1.88 (m, 4 H, H-2 and H-4) 2.16–2.50 (m, 2 H, H-3) 3.01 (br. s, 1 H, -OH) 
3.55 (d, J = 5.8 Hz, 2 H, H-8) 3.60–3.73 (m, 5 H, OCH3, H-5 and H-6) 3.98–4.05 (m, 1 H, H-7) 4.51–4.54 (m, 3 H, 
CH2Ph) 4.56–4.58 (m, 1 H, CH2Ph) 4.66 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.72 (d, J = 11.4 Hz, 1 H, CH2Ph) 7.25–7.41 
(m, 15 H, arom. H).
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13C NMR (75 MHz, CDCl3) δ 20.99, 30.27, 33.94, 51.48, 69.86, 71.06, 72.71, 73.42, 73.78, 78.97, 79.41, 127.71, 
127.74, 127.85, 127.89, 127.96, 128.09, 128.38, 128.41, 138.03, 138.08, 173.83.
Exact mass (ESI-MS) for C30H36KO6 [M + K]+ found, 531.2151; Calcd., 531.2143.
(5R,6S,7S)-methyl 7-azido-5,6,8- tri-O-benzyl-octanoate (19). To a solution of compound 13 (3.09 g, 6.27 mmol) 
in anhydrous THF (100 mL) were added PPh3 (3.29 g, 12.54 mmol), diethylazodicarboxylate (2.18 g, 5.7 mL, 
12.54 mmol), and diphenylphosphorylazide (3.45 g, 2.71 mL, 12.54 mmol) at −20 °C. After addition, the reaction 
mixture was allowed to warm to room temperature and stirred for 7 h. The solvent was evaporated under reduced 
pressure to give an orange residue. Purification by silica gel chromatography (hexane/EtOAc: 9/1) afforded 19 
(3.19 g, 95% yield) as a yellow oil.
1H-NMR (300 MHz CDCl3) δ 1.52–1.86 (m, 4 H, H-2 and H-4) 2.18–2.39 (m, 2 H, H-3) 3.55–3.83 (m, 8 H, 
OCH3, H-5, H-6, H-7 and H-8) 4.57–4.62 (m, 3 H, CH2Ph) 4.65 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.68 (d, J = 11.3 Hz, 
1 H, CH2Ph) 4.78 (d, J = 11.3 Hz, 1 H, CH2Ph) 7.18–7.46 (m, 15 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 20.72, 29.07, 33.94, 51.47, 61.93, 70.08, 71.95, 73.34, 73.83, 78.65, 78.74, 120.18, 
120.24, 126.09, 127.66, 127.69, 127.71, 127.77, 127.91, 128.00, 128.37, 128.38, 128.41, 130.03, 130.05, 137.81, 
137.91, 138.09, 173.84.
Exact mass (ESI-MS) for C30H35KN3O5 [M + K]+ found, 556.2210; Calcd., 556.2208.
(5R,6S,7S)-methyl 7-azido-5,6-di-O-benzyl-8-hydroxyoctanoate (12). Azide 19 (1.4 g, 2.7 mmol) and ZnCl2 
(7.38 g, 54 mmol) were dissolved in Ac2O/AcOH (2:1, 21 mL). The reaction was allowed to stir for 3.5 h at room 
temperature. Next H2O (10 mL) was added and the reaction mixture was extracted with CH2Cl2. The combined 
organic layers were washed with H2O, NaHCO3 (sat. aq.) and brine. Then the organic phase was dried over 
Na2SO4, filtered, and evaporated to afford 598 mg of crude acetate. The crude acetate was dissolved in MeOH 
(20 mL) and NaOMe (5.4 M solution in MeOH) was added till pH 10. After stirring overnight, Amberlite 120R 
(H+ form) was added to neutralize the reaction mixture. The mixture was diluted with MeOH (20 mL) and the 
exchange resin was filtered off and rinsed with MeOH. Evaporation of the filtrate under reduced pressure yielded 
a solid residue that was purified by silica gel chromatography (hexane/EtOAc: 7/3) to afford 12 (771 mg, 67% 
yield) as a colorless oil.
1H-NMR (300 MHz CDCl3) δ 1.56–1.87 (m, 4 H, H-5 and H-7) 2.25–2.34 (m, 2 H, H-6) 2.38 (t, J = 6.3 Hz, 
1 H, OH) 3.58–3.96 (m, 8 H, OCH3, H-1, H-2, H-3 and H-4) 4.58 (dd, J = 20.1 and 11.4 Hz, 2 H, CH2Ph) 4.68 (dd, 
J = 17.8 and 11.2 Hz, 2 H, CH2Ph) 7.24–7.41 (m, 10 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 20.79, 29.38, 33.82, 51.51, 62.31, 63.11, 72.38, 73.71, 78.60, 79.84, 127.88, 128.00, 
128.02, 128.11, 128.46, 128.52, 137.53, 137.75, 173.77.
Exact mass (ESI-MS) for C23H30N3O5 [M + H]+ found, 428.2177; Calcd., 428.2180.
(5R,6S,7S)-methyl-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-o
ctanoate (10). To a mixture of 11 (670 mg, 1.13 mmol) in THF (9 mL), a solution of 12 (323 mg, 0.76 mmol) in 
THF (6 mL) was added. The reaction mixture was cooled to −30 °C and TMSOTf (0.3 mL, 0.11 mmol) was added 
dropwise. After stirring for 2 h. at −30 °C, the reaction mixture was neutralized with Et3N and evaporated to 
dryness. The residue was purified by silica gel chromatography (hexane/EtOAc: 8/2 + 1% v/v Et3N) to afford 10 
(438 mg, 67% yield) as colorless liquid which solidified upon storage.
1H-NMR (300 MHz CDCl3) δ 1.46–1.79 (m, 4 H, CH2) 2.20 (t, J = 6.6 Hz, 2 H, CH2) 3.52 (br s., 1 H, H-4”) 
3.56–3.71 (m, 7 H, H-2, H-2”, H-4, Hb-6”, OCH3) 3.84 (dd, J = 12.5 and 1.5 Hz, 1 H, H-3”) 3.93 (dd, J = 9.8 and 
2.9 Hz, 1 H, Ha-1) 3.97–4.06 (m, 3 H, Hb-1, H-3 and Hb-6”) 4.13 (dd, J = 3.2 and 1.0 Hz, 1 H, H-5”) 4.43 (d, 
J = 11.5 Hz, 1 H, CH2Ph) 4.50–4.63 (m, 4 H, CH2Ph) 4.69 (d, J = 12.3 Hz, 1 H, CH2Ph) 4.76 (d, J = 12.5 Hz, 1 H, 
CH2Ph) 4.80 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.92 (d, J = 3.2 Hz, 1 H, H-1”) 5.41 (s, 1 H, H-8”) 7.14–7.36 (m, 23 H, 
arom. H) 7.44–7.48 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 20.83, 29.23, 33.89, 51.47, 61.65, 63.00, 68.31, 69.31, 71.95, 72.00, 73.54, 73.84, 
74.59, 75.41, 77.42, 78.42, 78.95, 99.14, 101.05, 126.33, 127.46, 127.50, 127.65, 127.69, 127.79, 127.83, 127.92, 
128.09, 128.22, 128.26, 128.39, 128.85, 137.82, 137.91, 138.11, 138.73, 138.75, 173.80.
Exact mass (ESI-MS) for C50H56N3O10 [M + H]+ found, 858.3948; Calcd., 858.3960.
General procedure for AlMe3 assisted amide coupling. To a solution of glycoside 10 (500 mg, 0.58 mmol) in anhy-
drous CH2Cl2 (10 mL) was added the appropriate amine (5 eq.) and AlMe3 (2 M in heptanes) (2.5 eq.). The reac-
tion mixture was stirred overnight at reflux temperature. Next the reaction mixture was cooled to 0 °C and water 
was added. The mixture was extracted with CH2Cl2 and the combined organic phase was washed with H2O 
and brine, dried over Na2SO4, filtered, and evaporated. Purification by column chromatography gave the desired 
amides 20a (61%), 20b (64%), 20c (64%), 20d (52%), 20e (51%), 20 f (68%), 20 g (81%), 20 h (60%).
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyran
osyl)-N-nonyloctanamide (20a). 1H-NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.5 Hz, 3 H, terminal CH3) 1.23–1.35 
(m, 12 H, CH2) 1.45 (dt, J = 13.4 and 7.8 Hz, 2 H, CH2) 1.53–1.81 (m, 4 H, CH2) 2.09 (t, J = 6.6 Hz, 2 H, CH2) 
3.14–3.24 (m, 2 H, NHCH2) 3.59–3.81 (m, 5 H, H-2, H-3, H-4, H-5” and Ha-6”) 3.93 (dd, J = 12.6 and 1.5 Hz, 
1 H, Ha-1) 3.98–4.04 (m, 1 H, Hb-6”) 4.06 (d, J = 3.2 Hz, 1 H, H-3”) 4.08–4.14 (m, 2 H, Hb-1 and H-2”) 4.20 (dd, 
J = 3.5 and 1.2 Hz, 1 H, H-4”) 4.49 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.59–4.72 (m, 4 H, CH2Ph) 4.75 (d, J = 12.3 Hz, 
1 H, CH2Ph) 4.82 (d, J = 12.3 Hz, 1 H, CH2Ph) 4.88 (d, J = 12.0 Hz, 1 H, CH2Ph) 4.98 (d, J = 3.3 Hz, 1 H, H-1”) 5.32 
(t, J = 5.1 Hz, 1 H, (CO)NH) 5.48 (s, 1 H, H-8”) 7.22–7.43 (m, 23 H, arom. H) 7.51–7.56 (m, 2 H, arom. H). 13C 
NMR (75 MHz, CDCl3) δ 14.10, 21.81, 22.65, 26.93, 29.25, 29.29, 29.50, 29.67, 31.84, 36.57, 39.50, 61.55, 63.03, 
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68.35, 69.33, 71.96, 72.02, 73.59, 73.87, 74.58, 75.38, 75.84, 78.35, 79.20, 99.19, 101.06, 126.34, 127.47, 127.52, 
127.68, 127.71, 127.75, 127.78, 127.89, 127.98, 128.11, 128.23, 128.27, 128.40, 128.43, 128.49, 128.87, 137.83, 
137.98, 138.14, 138.74, 172.41.
Exact mass (ESI-MS) for C58H76N5O9 [M + NH4]+ found, 986.5641; Calcd., 986.5638.
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
2-phenylethyl)octanamide (20b). 1H-NMR (300 MHz CDCl3) δ 1.52–1.76 (m, 4 H, CH2) 2.02–2.07 (m, 2 H, (CO)
CH2) 2.73 (t, J = 6.9 Hz, 2 H, H-11) 3.44 (q, J = 6.8 Hz, 2 H, NHCH2) 3.56 (app. s, 1 H, H-2) 3.57–3.63 (m, 2 H, 
H-4 and H-3) 3.66–3.75 (m, 2 H, H-5” and Ha-6”) 3.88 (dd, J = 12.3 and 1.3 Hz, 1 H, H-3”) 3.95 (d, J = 3.3 Hz, 
1 H, Ha-1) 3.97–4.06 (m, 2 H, H-2” and Hb-6”) 4.07–4.10 (m, 1 H, Hb-1) 4.15 (d, J = 2.9 Hz, 1 H, H-4”) 4.43 (d, 
J = 11.6 Hz, 1 H, CH2Ph) 4.54–4.66 (m, 4 H, CH2Ph) 4.71 (d, J = 12.4 Hz, 1 H, CH2Ph) 4.78 (d, J = 12.4 Hz, 1 H, 
CH2Ph) 4.83 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.93 (d, J = 3.2 Hz, 1 H, H-1”) 5.29 (t, J = 5.6 Hz, 1 H, (CO)NH) 5.43 (s, 
1 H, H-8”) 7.12–7.38 (m, 28 H, arom. H) 7.48 (dd, J = 7.3 and 2.3 Hz, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 21.71, 29.25, 35.70, 36.49, 40.49, 61.55, 63.03, 68.34, 69.32, 71.94, 72.01, 73.57, 
73.85, 74.56, 75.37, 75.83, 77.86, 78.28, 78.35, 78.70, 79.08, 79.63, 99.17, 101.04, 126.32, 126.49, 127.46, 127.50, 
127.66, 127.69, 127.76, 127.87, 127.95, 128.09, 128.21, 128.26, 128.38, 128.40, 128.61, 128.72, 128.85, 128.94, 
128.97, 129.15, 129.23, 129.37, 129.49, 129.54, 129.68, 129.89, 130.00, 137.81, 137.96, 138.12, 138.72, 138.87, 
140.00, 172.47.
Exact mass (ESI-MS) for C57H62N4NaO9 [M + Na]+ found, 969.4413; Calcd., 969.4409.
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(4-phenylbutyl)octanamide (20c). 1H-NMR (300 MHz CDCl3) δ 1.43–1.78 (m, 8 H, CH2) 2.07 (t, J = 6.8 Hz, 2 H, 
CH2) 2.62 (t, J = 7.5 Hz, 2 H, CH2) 3.21 (dd, J = 13.0 and 7.3 Hz, 2 H, NHCH2) 3.56 (app. s, 1 H, H-2) 3.60–3.67 
(m, 2 H, H-4 and Ha-6”) 3.69–3.79 (m, 2 H, H-5” and H-3) 3.91 (dd, J = 13.0 and 2.0 Hz, 1 H, Ha-1) 3.97–4.02 (m, 
1 H, Hb-6”) 4.04 (d, J = 2.9 Hz, 1 H, H-3”) 4.07–4.10 (m, 2 H, H-2” and Hb-1) 4.18 (d, J = 2.9 Hz, 1 H, H-4”) 4.47 
(d, J = 11.5 Hz, 1 H, CH2Ph) 4.57–4.69 (m, 4 H, CH2Ph) 4.74 (d, J = 12.6 Hz, 1 H, CH2Ph) 4.81 (d, J = 12.6 Hz, 1 H, 
CH2Ph) 4.86 (d, J = 11.9 Hz, 1 H, CH2Ph) 4.98 (d, J = 3.2 Hz, 1 H, H-1”) 5.29 (t, J = 5.2 Hz, 1 H, (CO)NH) 5.47 (s, 
1 H, H-8”) 7.14–7.41 (m, 28 H, arom. H) 7.49–7.53 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 21.79, 28.64, 29.22, 35.44, 36.54, 39.27, 61.55, 63.03, 68.35, 69.33, 71.95, 72.02, 
73.59, 73.87, 74.57, 75.38, 75.84, 77.21, 78.32, 79.18, 99.18, 101.05, 125.82, 126.33, 127.47, 127.52, 127.67, 127.70, 
127.75, 127.77, 127.87, 127.98, 128.10, 128.22, 128.27, 128.33, 128.37, 128.39, 128.42, 128.86, 137.81, 137.98, 
138.11, 138.72, 142.05, 172.45.
Exact mass (ESI-MS) for C59H67N4O9 [M + H]+ found, 975.4905; Calcd., 975.4903.
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(6-phenylhexyl)octanamide (20d). 1H-NMR (300 MHz CDCl3) δ 1.26–1.48 (m, 6 H, CH2) 1.52–1.78 (m, 6 H, 
CH2) 2.08 (t, J = 6.7 Hz, 2 H, CH2) 2.59 (t, J = 7.5 Hz, 2 H, CH2) 3.18 (dd, J = 13.4 and 7.2 Hz, 2 H, NHCH2) 3.59 
(app. s, 1 H, H-2) 3.61–3.67 (m, 2 H, H-3 and H-4) 3.68–3.79 (m, 2 H, H-5” and Ha-6”) 3.91 (dd, J = 12.7 and 
1.1 Hz, 1 H, Ha-1) 3.98–4.02 (m, 1 H, Hb-6”) 4.04 (d, J = 3.5 Hz, 1 H, H-3”) 4.07–4.12 (m, 2 H, Hb-1 and H-2”) 
4.19 (d, J = 2.7 Hz, 1 H, H-4”) 4.47 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.57–4.72 (m, 4 H, CH2Ph) 4.75 (d, J = 12.4 Hz, 
1 H, CH2Ph) 4.81 (d, J = 12.4 Hz, 1 H, CH2Ph) 4.86 (d, J = 12.1 Hz, 1 H, CH2Ph) 4.97 (d, J = 3.5 Hz, 1 H, H-1”) 
5.30 (t, J = 5.4 Hz, 1 H, (CO)NH) 5.47 (s, 1 H, H-8”) 7.15–7.42 (m, 28 H, arom. H) 7.50–7.54 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 21.80, 26.77, 28.89, 29.23, 29.58, 31.31, 35.84, 36.55, 39.43, 61.54, 63.02, 68.34, 
69.32, 71.95, 72.02, 73.57, 73.86, 74.56, 75.37, 75.83, 77.20, 78.33, 79.19, 99.17, 101.04, 125.62, 126.32, 127.46, 
127.51, 127.67, 127.70, 127.74, 127.76, 127.87, 127.96, 128.09, 128.22, 128.24, 128.26, 128.35, 128.38, 128.42, 
128.86, 137.81, 137.97, 138.11, 138.71, 142.59, 172.42.
Exact mass (ESI-MS) for C61H71N4O9 [M + H]+ found, 1003.5232; Calcd., 1003.5216.
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(8-phenyloctyl)octanamide (20e). 1H-NMR (300 MHz CDCl3) δ 1.23–1.49 (m, 10 H, CH2) 1.51–1.78 (m, 6 H, 
CH2) 2.08 (t, J = 6.0 Hz, 2 H, CH2) 2.59 (t, J = 7.5 Hz, 2 H, CH2) 3.18 (dd, J = 13.0 and 6.5 Hz, 2 H, NHCH2) 3.59 
(app. s, 1 H, H-2) 3.61–3.68 (m, 2 H, H-3 and H-4) 3.68–3.80 (m, 2 H, H-5” and Ha-6”) 3.91 (dd, J = 12.4 and 
1.4 Hz, 1 H, Ha-1) 4.98–4.03 (m, 1 H, Hb-6”) 4.04 (d, J = 3.2 Hz, 1 H, H-3”) 4.06–4.13 (m, 2 H, H-2” and Hb-1) 
4.19 (dd, J = 3.1 and 0.9 Hz, 1 H, H-4”) 4.47 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.56–4.71 (m, 4 H, CH2Ph) 4.75 (d, 
J = 12.4 Hz, 1 H, CH2Ph) 4.82 (d, J = 12.4 Hz, 1 H, CH2Ph) 4.86 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.98 (d, J = 3.2 Hz, 
1 H, H-1”) 5.31 (t, J = 5.1 Hz, 1 H, (CO)NH) 5.47 (s, 1 H, H-8”) 7.14–7.43 (m, 28 H, arom. H) 7.49–7.54 (m, 2 H, 
arom. H).
13C NMR (75 MHz, CDCl3) δ 21.82, 26.90, 29.22, 29.39, 29.66, 31.46, 35.95, 36.58, 39.48, 61.55, 63.03, 68.36, 
69.34, 71.96, 72.04, 73.58, 73.87, 74.59, 75.38, 75.84, 77.21, 78.34, 79.21, 99.20, 101.06, 110.00, 125.57, 126.34, 
127.48, 127.53, 127.68, 127.71, 127.76, 127.79, 127.89, 127.98, 128.11, 128.23, 128.27, 128.40, 128.43, 128.87, 
137.83, 137.98, 138.14, 138.73, 142.82, 172.42.
Exact mass (ESI-MS) for C63H75N4O9 [M + H]+ found, 1031.5575; Calcd., 1031.5529.
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(3-pentylphenyl)octanamide (20f). 1H-NMR (300 MHz CDCl3) δ 0.88 (t, J = 6.7 Hz, 3 H, terminal CH3) 
1.26–1.36 (m, 4 H, CH2) 1.54–1.65 (m, 4 H, CH2) 1.70–1.87 (m, 2 H, CH2) 2.26 (t, J = 6.9 Hz, 2 H, CH2) 2.56 (t, 
J = 8.0 Hz, 2 H, CH2) 3.54–3.59 (m, 2 H, H-2 and H-3) 3.62–3.69 (m, 2 H, H-4 and Ha-6”) 3.75 (dd, J = 6.7 and 
3.6 Hz, 1 H, H-5”) 3.85 (dd, J = 12.4 and 1.2 Hz, 1 H, Ha-1) 3.93–4.07 (m, 4 H, H-2”, H-3”, Hb-1 and Hb-6”) 4.13 
(d, J = 2.7 Hz, 1 H, H-4”) 4.43 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.64–4.52 (m, 4 H, CH2Ph) 4.68 (d, J = 12.5 Hz, 1 H, 
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CH2Ph) 4.75 (d, J = 12.5 Hz, 1 H, CH2Ph) 4.81 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.91 (d, J = 3.2 Hz, 1 H, H-1”) 5.40 (s, 
1 H, H-8”) 6.85 (d, J = 7.2 Hz, 1 H, arom. H) 6.99 (s, 1 H, (CO)NH) 7.08–7.37 (m, 26 H, arom. H) 7.46 (dd, J = 7.3 
and 2.2 Hz, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 14.03, 21.78, 22.52, 28.95, 31.09, 31.52, 35.93, 37.45, 61.49, 63.04, 68.27, 69.32, 
71.91, 72.06, 73.61, 73.95, 74.54, 75.38, 75.84, 77.21, 78.19, 79.37, 99.17, 101.05, 116.85, 116.95, 119.63, 124.29, 
126.33, 127.48, 127.52, 127.67, 127.71, 127.79, 127.85, 127.94, 128.10, 128.23, 128.27, 128.39, 128.50, 128.75, 
128.86, 137.78, 137.82, 137.91, 138.01, 138.72, 143.97, 170.72.
Exact mass (ESI-MS) for C60H68N4NaO9 [M + Na]+ found, 1011.4886; Calcd., 1011.4879.
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-
(4-pentylphenyl)octanamide (20g). 1H-NMR (300 MHz CDCl3) δ 0.88 (t, J = 6.8 Hz, 3 H, terminal CH3) 
1.29–1.31 (m, 3 H, CH2) 1.55–1.67 (m, 5 H, CH2) 1.71–1.89 (m, 2 H, CH2) 2.26 (t, J = 6.8 Hz, 2 H, CH2) 2.57 (t, 
J = 7.6 Hz, 2 H, CH2) 3.59–3.67 (m, 2 H, H-2 and H-5”) 3.67–3.77 (m, 2 H, H-4 and Ha-6”) 3.82 (dd, J = 6.8 and 
3.6 Hz, 1 H, H-3) 3.92 (dd, J = 12.5 and 1.5 Hz, 1 H, Ha-1) 3.98–4.14 (m, 4 H, Hb-1, H-2”, H-3” and Hb-6”) 4.20 
(d, J = 2.5 Hz, 1 H, H-4”) 4.50 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.58–4.72 (m, 4 H, CH2Ph) 4.75 (d, J = 12.3 Hz, 1 H, 
CH2Ph) 4.82 (d, J = 12.3 Hz, 1 H, CH2Ph) 4.88 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.98 (d, J = 3.2 Hz, 1 H, H-1”) 5.47 (s, 
1 H, H-8”) 7.04–7.14 (m, 3 H, arom. H) 7.22–7.43 (m, 25 H, (CO)NH and arom. H) 7.51–7.56 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 14.02, 21.77, 22.52, 28.96, 31.18, 31.41, 35.30, 37.36, 61.50, 63.03, 68.26, 69.32, 
71.91, 72.05, 73.60, 73.93, 74.54, 75.38, 75.83, 77.20, 78.21, 79.30, 99.16, 101.04, 119.77, 126.33, 127.48, 127.51, 
127.67, 127.71, 127.78, 127.84, 127.94, 128.10, 128.22, 128.26, 128.39, 128.49, 128.81, 128.86, 135.43, 137.82, 
137.91, 138.01, 138.71, 138.91, 170.66.
Exact mass (ESI-MS) for C60H68N4NaO9 [M + Na]+ found, 1011.4874; Calcd., 1011.4879.
(5R,6S,7S)-7-azido-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-N-(2-
(2-ethoxyethoxy)ethyl)octanamide (20 h). 1H-NMR (300 MHz CDCl3) δ 1.17 (t, J = 7.0 Hz, 3 H, terminal CH3) 
1.46–1.75 (m, 4 H, CH2) 1.99–2.08 (m, 2 H, CH2) 3.39 (q, 2 H, J = 5.2 Hz, NHCH2) 3.43–3.62 (m, 11 H, CH2, H-2, 
H-3 and H-4) 3.63–3.73 (m, 2 H, H-5” and Ha-6”) 3.85 (dd, J = 12.6 and 1.8 Hz, 1 H, Ha-1) 3.91–3.97 (m, 1 H, 
Hb-6”) 3.99 (d, J = 3.0 Hz, 1 H, H-3”) 4.00–4.07 (m, 2 H, Hb-1 and H-2”) 4.13 (d, J = 3.0 Hz, 1 H, H-4”) 4.43 (d, 
J = 11.5 Hz, 1 H, CH2Ph) 4.54 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.59–4.64 (m, 3 H, CH2Ph) 4.69 (d, J = 12.6 Hz, 1 H, 
CH2Ph) 4.76 (d, J = 12.6 Hz, 1 H, CH2Ph) 4.81 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.92 (d, J = 3.2 Hz, 1 H, H-1”) 5.41 (s, 
1 H, H-8”) 5.86 (t, J = 5.5 Hz, 1 H, (CO)NH) 7.16–7.37 (m, 23 H, arom. H) 7.44–7.48 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 15.60, 22.06, 29.82, 36.89, 39.50, 62.02, 63.43, 67.07, 68.78, 69.75, 70.14, 70.29, 
70.71, 72.39, 72.45, 73.97, 74.26, 75.01, 75.82, 76.24, 77.63, 78.87, 79.50, 99.57, 101.47, 126.76, 127.88, 127.93, 
128.10, 128.12, 128.19, 128.33, 128.52, 128.64, 128.69, 128.81, 128.82, 129.27, 138.25, 138.40, 138.58, 139.16, 
172.98.
Exact mass (ESI-MS) for C55H67N4O11 [M + H]+ found, 959.4799; Calcd., 959.4801.
Representative procedure for Staudinger reduction and acylation with EDC. To a solution of azide 20c (350 mg, 
0.36 mmol, 1eq.) in THF (5 mL) at room temperature, PMe3 (1 M solution of in THF, 5.38 mL, 5.38 mmol, 15 eq.) 
was added dropwise. After stirring for 3 h at room temperature, H2O (2 mL) was added and the reaction mixture 
was allowed to stir overnight at room temperature. Then the solvent was removed under reduced pressure. The 
crude product was dried by making azeotropic mixture with toluene to afford the crude amine. A mixture of the 
crude amine, EDC (112 mg, 0.72 mmol, 2 eq.) and octanoic acid (78 mg, 0.09 mL, 0.54 mmol, 1.5 eq.) in CH2Cl2 
(10 mL) was stirred for 24 h at room temperature. The reaction mixture was diluted with CH2Cl2, washed with 
H2O (2 × 10 mL) and brine (1 × 10 mL), dried over Na2SO4, filtered, and evaporated to dryness. Purification by 
silica gel chromatography gave the desired the desired amides. 21a (74%), 21b (76%), 21c (82%), 21d (80%), 21e 
(81%), 21 f (87%), 21 g (87%), 21 h (70%).
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α -D-galactopyranosyl)-
7-octanamido-N-nonyloctanamide (21a). 1H-NMR (300 MHz CDCl3) δ 0.85 (app. td, J = 6.7 and 2.8 Hz, 6 H, 
2 x terminal CH3) 1.19–1.35 (m, 18 H, CH2) 1.39–1.54 (m, 4 H, CH2) 1.60–1.83 (m, 6 H, CH2) 1.90–1.97 (m, 2 H, 
CH2) 2.02–2.10 (m, 2 H, CH2) 3.17 (dd, J = 12.9 and 6.9 Hz, 2 H, NHCH2)3.44 (m, 1 H, H-4) 3.52 (app. s, 1 H, 
H-5”) 3.74 (dd, J = 7.0 and 2.0 Hz, 1 H, H-3) 3.82 (d, J = 4.8 Hz, 2 H, H-1) 3.89–3.96 (m, 2 H, H-4” and Ha-6”) 4.04 
(d, J = 3.6 Hz, 1 H, H-2”) 4.07–4.14 (m, 2 H, H-2 and Hb-6”) 4.18 (d, J = 3.2 Hz, 1 H, H-3”) 4.39 (d, J = 11.6 Hz, 
1 H, CH2Ph) 4.47 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.55 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.62 (d, J = 11.8 Hz, 1 H, CH2Ph) 
4.72–4.77 (m, 3 H, CH2Ph) 4.84 (d, J = 11.8 Hz, 1 H, CH2Ph) 4.93 (d, J = 3.4 Hz, 1 H, H-1”) 5.45 (s, 1 H, H-8”) 5.98 
(d, J = 8.4 Hz, 1 H, NH(CO)) 6.05 (t, J = 5.7 Hz, 1 H, (CO)NH) 7.19–7.40 (m, 23 H, arom. H) 7.47–7.52(m, 2 H, 
arom. H).
13C NMR (75 MHz, CDCl3) δ 14.09, 21.84, 22.64, 25.65, 26.99, 28.82, 29.07, 29.26, 29.33, 29.52, 29.60, 31.76, 
31.84, 36.03, 36.65, 39.48, 50.02, 63.00, 68.08, 69.36, 71.52, 71.72, 73.28, 73.98, 74.18, 75.61, 76.10, 78.88, 99.60, 
101.01, 126.27, 127.57, 127.63, 127.70, 127.75, 127.86, 127.89, 127.92, 128.11, 128.31, 128.38, 128.41, 128.88, 
137.73, 138.23, 138.26, 138.39, 138.55, 172.81, 173.01.
Exact mass (ESI-MS) for C66H89N2O10 [M + H]+ found, 1069.6512; Calcd., 1069.6517.
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-octanamido-N-
(2-phenylethyl)octanamide (21b). 1H-NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.20–1.33 
(m, 7 H, CH2) 1.44–1.82 (m, 7 H, CH2) 1.88–1.98 (m, 2 H, CH2) 2.02–2.07 (m, 2 H, CH2) 2.78 (t, J = 7.3 Hz, 2 H, 
CH2) 3.40–3.54 (m, 4 H, H-4, H-5” and CH2) 3.75 (dd, J = 7.0 and 2.4 Hz, 1 H, H-3) 3.79–3.94 (m, 3 H, H-1 and 
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Ha-6”) 3.96 (d, J = 3.3 Hz, 1 H, H-4”) 4.07 (d, J = 3.3 Hz, 1 H, H-2”) 4.08–4.16 (m, 2 H, H-2 and Hb-6”) 4.18 (d, 
J = 3.2 Hz, 1 H, H-3”) 4.41 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.50 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.57 (d, J = 11.7 Hz, 
1 H, CH2Ph) 4.64 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.74–4.79 (m, 3 H, CH2Ph) 4.86 (d, J = 11.3 Hz, 1 H, CH2Ph) 4.96 
(d, J = 3.6 Hz, 1 H, H-1”) 5.46 (s, 1 H, H-8”) 5.98 (d, J = 8.5 Hz, 1 H, NH(CO)) 6.14 (t, J = 5.6 Hz, 1 H, (CO)NH) 
7.15–7.42 (m, 28 H, arom. H) 7.50–7.54 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 14.09, 21.77, 22.63, 25.67, 28.83, 29.08, 29.32, 31.77, 35.70, 36.00, 36.66, 40.60, 
50.03, 62.99, 68.06, 69.35, 71.50, 71.73, 73.31, 74.02, 74.14, 75.64, 76.09, 76.57, 77.20, 77.43, 78.85, 78.88, 99.56, 
101.01, 126.27, 126.33, 127.59, 127.64, 127.71, 127.79, 127.85, 127.91, 127.93, 128.11, 128.33, 128.36, 128.39, 
128.42, 128.50, 128.71, 128.89, 137.73, 138.24, 138.27, 138.36, 138.54, 139.09, 172.92, 173.08.
Exact mass (ESI-MS) for C65H79N2O10 [M + H]+ found, 1047.5768; Calcd., 1047.5729.
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-octanamido-N-
(4-phenylbutyl)octanamide (21c). 1H-NMR (300 MHz CDCl3) δ 0.86 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.17–1.28 
(m, 9 H, CH2) 1.40–1.51 (m, 4 H, CH2) 1.53–1.81 (m, 7 H, CH2) 1.82–2.08 (m, 2 H, CH2) 2.57 (t, J = 7.5 Hz, 2 H, 
CH2) 3.19 (q, J = 6.6 Hz, 2 H, NHCH2) 3.43–3.51 (m, 2 H, H-4 and H-5”) 3.72 (dd, J = 6.8 and 1.6 Hz, 1 H, H-3) 
3.80 (d, J = 4.8 Hz, 2 H, H-1) 3.87–3.95 (m, 2 H, H-4” and Ha-6”) 4.04 (d, J = 3.2 Hz, 1 H, H-2”) 4.06–4.14 (m, 2 H, 
H-2 and Hb-6”) 4.17 (d, J = 3.0 Hz, 1 H, H-3”) 4.38 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.46 (d, J = 11.5 Hz, 1 H, CH2Ph) 
4.54 (d, J = 11.7 Hz, 1 H, CH2Ph) 4.61 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.71–4.77 (m, 3 H, CH2Ph) 4.84 (d, J = 11.6 Hz, 
1 H, CH2Ph) 4.92 (d, J = 3.4 Hz, 1 H, H-1”) 5.44 (s, 1 H, H-8”) 5.91 (d, J = 8.5 Hz, 1 H, NH(CO)) 6.08 (t, J = 5.4 Hz, 
1 H, (CO)NH) 7.09–7.40 (m, 28 H, arom. H) 7.46–7.52 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 14.08, 21.80, 22.63, 25.65, 28.70, 28.77, 29.07, 29.18, 29.31, 31.76, 35.49, 35.96, 
36.65, 39.24, 50.03, 63.00, 68.10, 69.36, 71.51, 71.74, 73.30, 73.99, 74.16, 75.61, 76.10, 77.20, 78.86, 99.64, 101.01, 
125.72, 126.27, 127.56, 127.63, 127.72, 127.76, 127.88, 127.89, 127.91, 128.11, 128.27, 128.32, 128.34, 128.39, 
128.42, 128.89, 129.96, 137.72, 138.22, 138.24, 138.39, 138.55, 142.18, 172.94, 173.06.
Exact mass (ESI-MS) for C67H83N2O10 [M + H]+ found, 1075.6052; Calcd., 1075.6042.
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-octanamido-N-
(6-phenylhexyl)octanamide (21d). 1H-NMR (300 MHz CDCl3) δ 0.86 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.16–1.37 
(m, 12 H, CH2) 1.38–1.83 (m, 10 H, CH2) 1.87–2.11 (m, 4 H, CH2) 2.56 (t, J = 7.5 Hz, 2 H, CH2) 3.16 (q, J = 7.5 Hz, 
2 H, NHCH2) 3.44–3.56 (m, 2 H, H-4 and H-5”) 3.74 (dd, J = 6.8 and 2.4 Hz, 1 H, H-3) 3.82 (d, J = 4.6 Hz, 2 H, 
H-1) 3.88–3.99 (m, 2 H, H-4” and Ha-6”) 4.05 (d, J = 3.3 Hz, 1 H, H-2”) 4.07–4.15 (m, 2 H, H-2 and Hb-6”) 4.18 
(d, J = 3.2 Hz, 1 H, H-3”) 4.39 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.48 (d, J = 11.4 Hz, 1 H, CH2Ph) 4.55 (d, J = 11.4 Hz, 
1 H, CH2Ph) 4.62 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.72–4.79 (m, 3 H, CH2Ph) 4.84 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.93 
(d, J = 3.5 Hz, 1 H, H-1”) 5.45 (s, 1 H, H-8”) 5.93 (d, J = 8.4 Hz, 1 H, NH(CO)) 6.04 (t, J = 5.7 Hz, 1 H, (CO)NH) 
7.11–7.43 (m, 28 H, arom. H) 7.48–7.52 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 14.08, 21.83, 22.63, 25.65, 26.82, 28.83, 28.94, 29.07, 29.31, 29.53, 31.35, 31.75, 
35.85, 36.03, 36.66, 39.42, 50.04, 63.00, 68.14, 69.36, 71.53, 71.75, 73.28, 73.96, 74.19, 75.61, 76.11, 77.21, 78.90, 
99.66, 101.01, 125.58, 126.27, 127.55, 127.62, 127.71, 127.74, 127.88, 127.91, 128.11, 128.21, 128.32, 128.34, 
128.39, 128.42, 128.89, 137.73, 138.23, 138.25, 138.42, 138.56, 142.64, 172.82, 173.00.
Exact mass (ESI-MS) for C69H86N2NaO10 [M + Na]+ found, 1125.6173; Calcd., 1125.6175.
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-octanamido-N-
(8-phenyloctyl)octanamide (21e). 1H-NMR (300 MHz CDCl3) δ 0.87 (t, J = 6.9 Hz, 3 H, terminal CH3) 1.17–1.35 
(m, 14 H, CH2) 1.37–1.84 (m, 12 H, CH2) 1.87–2.00 (m, 2 H, CH2) 2.02–2.11 (m, 2 H, CH2) 2.58 (t, J = 7.6 Hz, 
2 H, CH2) 3.16 (dd, J = 12.8 and 7.5 Hz, 2 H, NH-CH2) 3.45–3.51 (m, 1 H, H-4) 3.53 (br. s, 1 H, H-5”) 3.75 (dd, 
J = 6.8 and 2.3 Hz, 1 H, H-3) 3.84 (d, J = 4.9 Hz, 2 H, H-1) 3.88–3.97 (m, 2 H, H-4” and Ha-6”) 4.05 (d, J = 3.4 Hz, 
1 H, H-2”) 4.07–4.17 (m, 2 H, H-2 and Hb-6”) 4.19 (d, J = 2.9 Hz, 1 H, H-3”) 4.42 (d, J = 11.6 Hz, 1 H, CH2Ph) 
4.54 (dd, J = 22.3 and 11.4 Hz, 2 H, CH2Ph) 4.65 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.75–4.80 (m, 3 H, CH2Ph) 4.87 (d, 
J = 11.6 Hz, 1 H, CH2Ph) 4.96 (d, J = 3.5 Hz, 1 H, H-1”) 5.48 (s, 1 H, H-8”) 5.93 (d, J = 8.5 Hz, 1 H, NH(CO)) 6.04 
(t, J = 5.6 Hz, 1 H, (CO)NH) 7.14–7.21 (m, 2 H, arom. H) 7.21–7.42 (m, 26 H, arom. H) 7.49–7.55 (m, 2 H, arom. 
H).
13C NMR (75 MHz, CDCl3) δ 14.08, 21.85, 22.63, 25.65, 26.96, 28.82, 29.08, 29.25, 29.31, 29.42, 29.60, 31.46, 
31.77, 35.94, 36.04, 36.65, 39.46, 50.03, 63.00, 68.07, 69.37, 71.52, 71.73, 73.31, 73.99, 74.18, 75.61, 76.10, 77.20, 
78.88, 78.91, 99.61, 101.03, 125.54, 126.28, 127.59, 127.63, 127.71, 127.77, 127.86, 127.91, 128.12, 128.20, 128.32, 
128.35, 128.40, 128.43, 128.90, 137.74, 138.24, 138.38, 138.56, 142.82, 172.82, 173.02.
Exact mass (ESI-MS) for C71H90N2NaO10 [M + Na]+ found, 1153.6510; Calcd., 1153.6488.
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-octanamido-N-
(3-pentylphenyl)octanamide (21f). 1H-NMR (300 MHz CDCl3) δ 0.83–0.88 (m, 6 H, 2 x terminal CH3) 1.22–1.33 
(m, 12 H, CH2) 1.47–1.83 (m, 7 H, CH2) 1.85–2.03 (m, 3 H, CH2) 2.11–2.25 (m, 2 H, CH2) 2.54 (t, J = 7.4 Hz, 
2 H, CH2) 3.46–3.53 (m, 2 H, H-4 and H-5”) 3.73 (dd, J = 7.7 and 1.5 Hz, 1 H, H-3) 3.80 (d, J = 4.9 Hz, 2 H, H-1) 
3.85–3.93 (m, 1 H, Ha-6”) 3.95 (d, J = 3.3 Hz, 1 H, H-4”) 4.05 (d, J = 3.5 Hz, 1 H, H-2”) 4.07–4.14 (m, 2 H, H-2 and 
Hb-6”) 4.17 (d, J = 3.3 Hz, 1 H, H-3”) 4.38 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.48 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.57 (d, 
J = 11.6 Hz, 1 H, CH2Ph) 4.62 (d, J = 11.5 Hz, 1 H, CH2Ph) 4.74–4.80 (m, 3 H, CH2Ph) 4.86 (d, J = 11.4 Hz, 1 H, 
CH2Ph) 4.94 (d, J = 3.6 Hz, 1 H, H-1”) 5.44 (s, 1 H, H-8”) 6.00 (d, J = 8.6 Hz, 1 H, NH(CO)) 6.86 (d, J = 7.6 Hz, 
1 H, arom. H) 7.12 (t, J = 7.9 Hz, 1 H, arom. H) 7.21–7.41 (m, 24 H, arom. H) 7.44–7.53 (m, 3 H, arom. H) 8.36 (s, 
1 H, (CO)NH).
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13C NMR (75 MHz, CDCl3) δ 14.03, 21.67, 22.53, 22.63, 25.70, 29.09, 29.33, 31.10, 31.54, 31.78, 36.01, 36.72, 
50.00, 63.04, 67.99, 69.32, 71.49, 71.70, 73.26, 74.02, 74.13, 75.59, 76.10, 78.63, 99.55, 101.01, 116.86, 119.69, 
123.80, 126.27, 127.56, 127.65, 127.73, 127.78, 127.82, 127.90, 127.93, 128.00, 128.12, 128.34, 128.37, 128.41, 
128.45, 128.90, 137.74, 138.10, 138.14, 138.44, 138.56, 143.74, 171.59, 173.24.
Exact mass (ESI-MS) for C68H84KN2O10 [M + K]+ found, 1127.5773; Calcd., 1127.5758.
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-octanamido-N-
(4-pentylphenyl)octanamide (21g). 1H-NMR (300 MHz CDCl3) δ 0.86–0.93 (m, 6 H, 2 x terminal CH3) 1.22–
1.38 (m, 12 H, CH2) 1.50–1.84 (m, 6 H, CH2) 1.87–2.07 (m, 3 H, CH2) 2.09–2.28 (m, 2 H, CH2) 2.54 (t, J = 7.1 Hz, 
2 H, CH2) 3.46–3.54 (m, 2 H, H-4 and H-5”) 3.75 (dd, J = 8.0, 1.2 Hz, 1 H, H-3) 3.79–3.83 (m, 2 H, H-1) 3.89 (dd, 
J = 12.5 and 1.3 Hz, 1 H, Ha-6”) 3.95 (dd, J = 10.0 and 3.5 Hz, 1 H, H-4”) 4.08 (d, J = 3.5 Hz, 1 H, H-2”) 4.09–4.16 
(m, 2 H, H-2 and Hb-6”) 4.19 (d, J = 2.8 Hz, 1 H, H-3”) 4.39 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.49 (d, J = 11.6 Hz, 1 H, 
CH2Ph) 4.59 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.64 (d, J = 11.3 Hz, 1 H, CH2Ph) 4.76–4.83 (m, 3 H, CH2Ph) 4.88 (d, 
J = 11.3 Hz, 1 H, CH2Ph) 4.95 (d, J = 3.5 Hz, 1 H, H-1”) 5.46 (s, 1 H, H-8”) 6.16 (d, J = 8.7 Hz, 1 H, NH(CO)) 7.06 
(d, J = 8.5 Hz, 2 H, arom. H) 7.22–7.37(m, 22 H, arom. H) 7.38–7.46 (m, 3 H, arom. H) 7.49–7.5(m, 2 H, arom. H) 
8.49 (s, 1 H, (CO)NH).
13C NMR (75 MHz, CDCl3) δ 14.02, 14.04, 14.08, 21.68, 22.52, 22.58, 22.63, 24.75, 25.69, 28.11, 28.90, 29.03, 
29.09, 29.34, 31.23, 31.43, 31.62, 31.78, 33.64, 35.34, 36.51, 36.70, 49.97, 63.01, 67.87, 69.31, 71.50, 71.66, 73.27, 
74.07, 74.12, 75.60, 76.07, 77.20, 78.55, 99.40, 101.01, 119.67, 126.27, 127.59, 127.68, 127.71, 127.82, 127.90, 
127.94, 127.98, 128.12, 128.35, 128.37, 128.41, 128.44, 128.59, 128.90, 136.28, 137.72, 138.09, 138.14, 138.28, 
138.35, 138.53, 171.57, 173.39.
Exact mass (ESI-MS) for C68H85N2O10 [M + H]+ found, 1089.6204; Calcd., 1089.6199.
(5R,6S,7S)-5,6-di-O-benzyl-8-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl)-7-octanamido-N-(2-
(2-ethoxyethoxy)ethyl)octanamide (21 h). 1H-NMR (300 MHz CDCl3) δ 0.89 (t, J = 6.8 Hz, 3 H, terminal CH3) 
1.18–1.35 (m, 12 H, CH2 and terminal CH3) 1.45–1.56 (m, 2 H, CH2) 1.60–1.88 (m, 3 H, CH2) 1.89–1.97 (m, 2 H, 
CH2) 2.10 (t, J = 6.2 Hz, 2 H, CH2) 3.40–3.48 (m, 2 H, CH2) 3.50–3.62 (m, 10 H, H-4, H-5” and CH2) 3.78 (dd, 
J = 6.1 and 2.4 Hz, 1 H, H-3) 3.80–3.99 (m, 4 H, CH2-1, H-2 and Ha-6”) 4.07 (d, J = 3.3 Hz, 1 H, H-4”) 4.10–4.18 
(m, 1 H, Hb-6”) 4.19–4.25 (m, 2 H, H-2” and H-3”) 4.46 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.51 (d, J = 11.6 Hz, 1 H, 
CH2Ph) 4.59 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.65 (d, J = 11.6 Hz, 1 H, CH2Ph) 4.73–4.78 (m, 3 H, CH2Ph) 4.87 (d, 
J = 11.4 Hz, 1 H, CH2Ph) 4.96 (d, J = 3.4 Hz, 1 H, H-1”) 5.48 (s, 1 H, H-8”) 5.89 (d, J = 8.4 Hz, 1 H, NH(CO)) 6.26 
(t, J = 5.3 Hz, 1 H, (CO)NH) 7.22–7.44 (m, 23 H, arom. H) 7.51–7.55 (m, 2 H, arom. H).
13C NMR (75 MHz, CDCl3) δ 14.08, 15.16, 21.82, 22.63, 25.67, 29.06, 29.16, 29.31, 31.75, 36.13, 36.68, 39.04, 
50.12, 62.96, 66.61, 68.11, 69.38, 69.70, 69.81, 70.22, 71.57, 71.78, 73.30, 73.90, 74.23, 75.64, 76.12, 77.20, 78.94, 
79.16, 99.58, 101.00, 126.28, 127.56, 127.60, 127.67, 127.70, 127.72, 127.88, 127.90, 128.09, 128.30, 128.33, 128.38, 
128.41, 128.85, 137.77, 138.28, 138.30, 138.45, 138.60, 172.91, 173.00.
Exact mass (ESI-MS) for C63H83N2O12 [M + H]+ found, 1059.5945; Calcd., 1059.5941.
General procedure for debenzylation. A solution of the protected amide (0.06 mmol) in CHCl3 (3 mL) and EtOH 
(9 mL) was hydrogenated under atmospheric pressure in the presence of palladium black (35 mg). Upon reaction 
completion, the mixture was filtered through celite. The filter cake was rinsed with CHCl3 and EtOH and the fil-
trate was evaporated to dryness. After purification by silica gel chromatography (10% → 18% MeOH in CH2Cl2), 
final compounds 5a (43%), 5b (30%), 5c (42%), 5d (56%), 5e (56%), 5f (78%), 5g (71%), 5h (53%) were obtained 
as white powders.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-nonyloctanamide (5a). 1H-NMR 
(300 MHz, pyridine-d5) δ 0.77–0.91 (m, 6 H, 2 x terminal CH3) 1.08–1.38 (m, 20 H, CH2) 1.59 (dt, J = 14.8 and 
7.6 Hz, 2 H, CH2) 1.77 (dt, J = 14.8 and 7.6 Hz, 2 H, CH2) 1.92–2.04 (m, 1 H, CH2) 2.17–2.29 (m, 1 H, CH2) 2.34–
2.60 (m, 6 H, CH2) 3.46 (dd, J = 13.0 and 6.8 Hz, 2 H, NHCH2) 4.26–4.37 (m, 3 H, Ha-1, H-3 and H-4) 4.37–4.45 
(m, 3 H, H-4” and H-6”) 4.48 (q, J = 6.2 Hz, 1 H, H-3”) 4.55 (d, J = 2.9 Hz, 1 H, H-5”) 4.60–4.69 (m, 2 H, Hb-1 and 
H-2”) 5.19–5.28 (m, 1 H, H-2) 5.56 (d, J = 3.8 Hz, 1 H, H-1”) 6.36 (br. s, 6 H, OH) 8.30 (t, J = 5.2 Hz, 1 H, NH(CO)) 
8.46 (d, J = 8.6 Hz, 1 H, (CO)NH).
13C NMR (75 MHz, pyridine-d5) δ 14.60, 14.65, 23.23, 23.28, 23.47, 26.71, 27.78, 29.73, 29.88, 30.01, 30.18, 
30.38, 30.66, 32.27, 32.43, 34.38, 37.14, 37.35, 40.11, 51.78, 63.03, 68.98, 70.68, 71.37, 71.96, 72.61, 73.42, 77.19, 
101.92, 173.65.
Exact mass (ESI-MS) for C31H61N2O10 [M + H]+ found, 621.4347; Calcd., 621.4326; m.p.: 95–97 °C.
(5R,6 S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(2-phenylethyl)octanamide 
(5b). 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.2 Hz, 3 H, terminal CH3) 1.11–1.35 (m, 8 H, CH2) 1.77 
(dt, J = 14.6 and 7.3 Hz, 2 H, CH2) 1.89–2.04 (m, 1 H, CH2) 2.11–2.26 (m, 1 H, CH2) 2.31–2.55 (m, 6 H, CH2) 2.93 
(t, J = 7.2 Hz, 2 H, CH2Ph) 3.68 (q, J = 6.8 Hz, 2 H, NHCH2) 4.26–4.32 (m, 1 H, H-3) 4.32–4.54 (m, 6 H, H-4, Ha-1, 
H-4”, H-5” and CH2-6”) 4.56 (d, J = 2.5 Hz, 1 H, H-3”) 4.61–4.69 (m, 2 H, H-2” and Hb-1) 5.20–5.30 (m, 1 H, H-2) 
5.57 (d, J = 3.4 Hz, 1 H, H-1”) 7.24–7.35 (m, 3 H, arom. H) 8.43–8.54 (m, 2 H, arom. H).
13C NMR (75 MHz, pyridine-d5) δ 29.03, 37.66, 37.83, 41.15, 44.16, 44.44, 46.70, 48.82, 51.21, 51.58, 51.69, 
56.18, 66.16, 77.46, 83.33, 85.09, 85.81, 86.38, 87.06, 87.83, 91.60, 116.30, 141.31, 143.62, 144.10, 155.13, 188.15, 
188.27.
Exact mass (ESI-MS) for C30H51N2O10 [M + H]+ found, 599.3541; Calcd., 599.3538; m.p. 56–58 °C.
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(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(4-phenylbutyl)octanamide 
(5c). 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.07–1.42 (m, 10 H, CH2) 1.54–
1.67 (m, 4 H, CH2) 1.76 (dt, J = 14.9 and 7.5 Hz, 2 H, CH2) 1.90–2.04 (m, 1 H, CH2) 2.12–2.27 (m, 1 H, CH2) 
2.30–2.58 (m, 6 H, CH2) 3.44 (q, J = 5.8 Hz, 2 H, NHCH2) 4.25–4.44 (m, 6 H, Ha-1, H-3, H-4, H-4” and CH2-6”) 
4.48 (q, J = 5.7 Hz, 1 H, H-3”) 4.55 (d, J = 2.6 Hz, 1 H, H-5”) 4.60–4.68 (m, 2 H, Hb-1 and H-2”) 5.19–5.28 (m, 1 H, 
H-2) 5.56 (d, J = 3.8 Hz, 1 H, H-1”) 6.47 (br. s, 6 H, OH) 7.17–7.25 (m, 3 H, arom. H) 7.28–7.35 (m, 2 H, arom. H) 
8.28 (t, J = 5.3 Hz, 1 H, (CO)NH) 8.46 (d, J = 8.6 Hz, 1 H, NH(CO)).
13C NMR (75 MHz, pyridine-d5) δ 14.60, 23.23, 23.46, 26.72, 29.58, 29.72, 30.01, 30.21, 30.39, 32.27, 34.41, 
36.07, 37.14, 37.33, 39.79, 51.78, 63.04, 68.98, 70.68, 71.38, 71.97, 72.62, 73.43, 77.21, 101.92, 126.46, 129.09, 
129.23, 136.58, 143.22, 173.66, 173.67.
Exact mass (ESI-MS) for C32H55N2O10 [M + H]+ found, 627.3860; Calcd., 627.3851; m.p. 57–59 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(6-phenylhexyl)octana-
mide(5d). 1H-NMR (300 MHz, pyridine-d5) δ 0.77–0.87 (m, 3 H, terminal CH3) 1.09–1.43 (m, 13 H, CH2) 1.54 
(dt, J = 12.6 and 6.3 Hz, 3 H, CH2) 1.77 (dt, J = 14.4 and 7.1 Hz, 2 H, CH2) 1.91–2.05 (m, 1 H, CH2) 2.16–2.31 (m, 
1 H, CH2) 2.33–2.60 (m, 6 H, CH2) 3.03 (q, J = 7.0 Hz, 2 H, CH2) 3.43 (d, J = 5.8 Hz, 2 H, NHCH2) 4.27–4.46 (m, 
6 H, Ha-1, H-3, H-4, H-4” and CH2-6”) 4.46–4.53 (m, 1 H, H-5”) 4.56 (app. s, 1 H, H-3”) 4.60–4.69 (m, 2 H, Hb-1 
and H-2”) 5.19–5.29 (m, 1 H, H-2) 5.56 (d, J = 2.4 Hz, 1 H, H-1”) 6.40 (br. s, 6 H, OH) 7.19–7.29 (m, 3 H, arom. H) 
7.30–7.39 (m, 2 H, arom. H) 8.29 (t, J = 5.7, 1 H, (CO)NH) 8.49 (d, J = 8.2 Hz, 1 H, NH(CO)).
13C NMR (75 MHz, pyridine-d5) δ 8.91, 14.59, 23.22, 23.45, 26.70, 27.58, 29.58, 29.71, 29.99, 30.35, 30.53, 
32.08, 32.26, 34.37, 36.40, 37.13, 37.33, 40.05, 46.18, 51.78, 63.00, 68.92, 70.68, 71.34, 71.95, 72.56, 73.39, 77.17, 
101.89, 126.41, 129.07, 129.21, 143.51, 173.66, 173.68.
Exact mass (ESI-MS) for C34H59N2O10 [M + H]+ found, 655.4161; Calcd., 655.4164; m.p. 135–137 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(8-phenyloctyl)octanamide 
(5e). 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.3 Hz, 3 H, terminal CH3) 1.09–1.36 (m, 16 H, CH2) 1.47–
1.64 (m, 4 H, CH2) 1.69–1.83 (m, 2 H, CH2) 1.91–2.05 (m, 1 H, CH2) 2.14–2.30 (m, 1 H, CH2) 2.34–2.60 (m, 8 H, 
CH2) 3.45 (dd, J = 13.1 and 6.8 Hz, 2 H, NHCH2) 4.26–4.45 (m, 6 H, Ha-1, H-3, H-4, H-4” and CH2-6”) 4.49 (q, 
J = 6.0 Hz, 1 H, H-5”) 4.56 (d, J = 3.0 Hz, 1 H, H-3”) 4.61–4.69 (m, 2 H, Hb-1 and H-2”) 5.19–5.29 (m, 1 H, H-2) 
5.57 (d, J = 3.5 Hz, 1 H, H-1”) 6.56 (br. s, 6 H, OH) 7.21–7.29 (m, 3 H, arom. H) 7.33–7.40 (m, 2 H, arom. H) 8.30 
(t, J = 5.4, 1 H, (CO)NH) 8.48 (d, J = 8.5 Hz, 1 H, NH(CO)).
13C NMR (75 MHz, pyridine-d5) δ 8.91, 14.58, 23.21, 23.45, 26.69, 27.73, 29.71, 29.80, 29.89, 29.99, 30.03, 
30.61, 32.15, 32.26, 34.37, 36.47, 37.12, 37.33, 40.08, 46.18, 51.78, 63.00, 68.93, 70.67, 71.34, 71.95, 72.58, 73.40, 
77.17, 101.88, 126.42, 129.09, 129.24, 143.59, 173.66.
Exact mass (ESI-MS) for C36H63N2O10 [M + H]+ found, 683.4477; Calcd., 683.4477; m.p. 128–130 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(3-pentylphenyl)octanamide 
(5f). 1H-NMR (300 MHz, pyridine-d5) δ 0.81 (t, J = 6.5 Hz, 6 H, 2 x terminal CH3) 1.11–1.34 (m, 14 H, CH2) 
1.55 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.77 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.90–2.03 (m, 1 H, CH2) 2.17–2.31 
(m, 1 H, CH2) 2.41 (t, J = 7.6 Hz, 2 H, CH2) 2.55 (t, J = 7.6 Hz, 2 H, CH2) 2.68 (dd, J = 14.2 and 7.0 Hz, 2 H, CH2) 
4.24–4.31 (m, 1 H, H-3) 4.31–4.45 (m, 5 H, H-4, Ha-1, H-4” and H-6”) 4.48 (q, J = 5.4 Hz, 1 H, H-3”) 4.55 (d, 
J = 2.4 Hz, 1 H, H-5”) 4.60–4.69 (m, 2 H, H-2” and Hb-1) 5.20–5.29 (m, 1 H, H-2) 5.57 (d, J = 3.4 Hz, 1 H, H-1”) 
6.48 (br. s., 6 H, OH) 6.99 (d, J = 7.5 Hz, 1 H, arom. H) 7.32 (t, J = 7.7 Hz, 1 H, arom. H) 7.88 (d, J = 8.0 Hz, 1 H, 
arom. H) 7.98 (s, 1 H, arom. H) 8.47 (d, J = 8.7 Hz, 1 H, NH(CO)) 10.60 (s, 1 H, (CO)NH).
13C NMR (75 MHz, pyridine-d5) δ 14.51, 14.57, 23.10, 23.21, 23.41, 26.70, 29.70, 29.98, 31.76, 31.98, 32.25, 
34.30, 36.57, 37.11, 38.21, 51.65, 63.02, 68.80, 70.63, 71.37, 71.93, 72.61, 73.40, 77.15, 101.82, 117.89, 120.54, 
124.09, 129.41, 141.00, 144.22, 172.70, 173.69.
Exact mass (ESI-MS) for C33H57N2O10 [M + H]+ found, 641.4001; Calcd., 641.4008; m.p. 165–167 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(4-pentylphenyl)octanamide 
(5g). 1H-NMR (300 MHz, pyridine-d5) δ 0.81 (dt, J = 9.1 and 7.0 Hz, 6 H, 2 x terminal CH3) 1.12–1.34 (m, 14 H, 
CH2) 1.55 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.77 (dt, J = 14.9 and 7.5 Hz, 2 H, CH2) 1.89–2.05 (m, 1 H, CH2) 2.17–
2.33 (m, 1 H, CH2) 2.42 (t, J = 7.8 Hz, 2 H, CH2) 2.53 (t, J = 7.8 Hz, 2 H, CH2) 2.61–2.71 (m, 2 H, CH2) 4.24–4.45 
(m, 6 H, H-3, H-4, H-4”, H-6” and Ha-1) 4.49 (q, J = 5.9 Hz, 1 H, H-3”) 4.56 (d, J = 2.9 Hz, 1 H, H-5”) 4.61–4.69 
(m, 2 H, Hb-1 and H-2”) 5.20–5.29 (m, 1 H, H-2) 5.57 (d, J = 3.7 Hz, 1 H, H-1”) 6.41 (br. s, 6 H, OH) 7.23 (app. s, 
2 H, arom. H) 8.01 (d, J = 8.4 Hz, 2 H, arom. H) 8.48 (d, J = 8.7 Hz, 1 H, NH(CO)) 10.63 (s, 1 H, (CO)NH).
13C NMR (75 MHz, pyridine-d5) δ 14.55, 14.58, 23.14, 23.22, 23.42, 26.70, 29.71, 29.99, 31.95, 32.26, 34.31, 
35.86, 37.13, 38.14, 51.66, 63.04, 68.81, 70.66, 71.38, 71.95, 72.62, 73.42, 77.18, 101.85, 120.56, 129.43, 138.26, 
138.75, 172.58, 173.68.
Exact mass (ESI-MS) for C33H57N2O10 [M + H]+ found, 641.4011; Calcd., 641.4008; m.p. 147–149 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-octanamido-N-(2-(2-ethoxyethoxy)ethyl)octanamide 
(5h). 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.5 Hz, 3 H, terminal CH3) 1.08–1.22 (m, 8 H, terminal CH3 
and CH2) 1.23–1.41 (m, 5 H, CH2) 1.76 (dt, J = 14.8 and 7.4 Hz, 2 H, CH2) 1.87–2.01 (m, 1 H, CH2) 2.11–2.24 (m, 
1 H, CH2) 2.31–2.47 (m, 4 H, CH2) 2.47–2.58 (m, 2 H, CH2) 3.41 (q, J = 7.0 Hz, 2 H, CH2) 3.49–3.54 (m, 2 H, CH2) 
3.56–3.61 (m, 2 H, CH2) 3.62–3.70 (m, 2 H, CH2) 4.22–4.44 (m, 6 H, Ha-1, H-3, H-4, H-4” and CH2-6”) 4.48 (q, 
J = 5.8 Hz, 1 H, H-5”) 4.55 (d, J = 2.7 Hz, 1 H, H-3”) 4.60–4.69 (m, 2 H, Hb-1 an H-2”d) 5.19–5.29 (m, 1 H, H-2) 
5.56 (d, J = 3.7 Hz, 1 H, H-1”) 6.43 (br. s, 6 H, OH) 8.43 (d, J = 8.4 Hz, 1 H, NH(CO)) 8.47–8.52 (m, 1 H, (CO)NH).
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13C NMR (75 MHz, pyridine-d5) δ 14.59, 15.84, 23.23, 23.39, 26.71, 29.72, 30.00, 30.37, 32.27, 34.46, 37.14, 37.21, 
40.14, 51.74, 63.03, 66.84, 68.93, 70.50, 70.67, 70.85, 71.01, 71.38, 71.96, 72.64, 73.42, 77.21, 101.90, 173.64, 173.86.
Exact mass (ESI-MS) for C28H55N2O12 [M + H]+ found, 611.3750; Calcd., 611.3750; m.p. could not be deter-
mined due to hygroscopy.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-undecanamino-N-(6-phenylhexyl)octanamide 
(6d). 1H-NMR (300 MHz, pyridine-d5) δ 0.87 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.13–1.41 (m, 20 H, CH2) 1.45–
1.61 (m, 4 H, CH2) 1.73–1.87 (m, 2 H, CH2) 1.91–2.05 (m, 1 H, CH2) 2.18–2.60 (m, 9 H, CH2) 3.43 (q, J = 6.8 Hz, 
2 H, NHCH2) 4.26–4.53 (m, 7 H, Ha-1, H-3, H-4, H-4”, H-5” and CH2-6”) 4.56 (d, J = 3.1 Hz, 1 H, H-3”) 4.61–4.71 
(m, 2 H, Hb-1 and H-2”) 5.21–5.31 (m, 1 H, H-2) 5.57 (d, J = 3.8 Hz, 1 H, H-1”) 5.96 (br. s, 6 H, OH) 7.17–7.27 (m, 
3 H, arom. H) 7.31–7.38 (m, 2 H, arom. H) 8.27 (t, J = 5.8 Hz, 1 H, (CO)NH) 8.48 (d, J = 8.7 Hz, 1 H, NH(CO)).
13C NMR (75 MHz, pyridine-d5) δ 14.69, 23.33, 23.47, 26.77, 27.59, 29.62, 29.99, 30.14, 30.20, 30.26, 30.32, 
30.55, 32.11, 32.51, 34.41, 36.43, 37.18, 37.34, 40.08, 51.77, 63.05, 68.96, 70.70, 71.40, 71.98, 72.62, 73.45, 77.22, 
101.93, 126.45, 129.10, 129.24, 143.53, 173.68, 173.72.
Exact mass (ESI-MS) for C38H67N2O10 [M + H]+ found, 711.4781; Calcd., 711.4790; m.p. 91–93 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-pentadecanamino-N-(6-phenylhexyl)octanamide 
(7d). 1H-NMR (300 MHz, pyridine-d5) δ 0.88 (t, J = 6.7 Hz, 3 H, terminal CH3) 1.16–1.41 (m, 28 H, CH2) 1.45–
1.61 (m, 4 H, CH2) 1.74–1.87 (m, 2 H, CH2) 1.91–2.04 (m, 1 H, CH2) 2.16–2.60 (m, 9 H, CH2) 3.43 (q, J = 6.7 Hz, 
2 H, NHCH2) 4.26–4.53 (m, 7 H, Ha-1, H-3, H-4, H-4”, H-5” and CH2-6”) 4.56 (d, J = 3.2 Hz, 1 H, H-3”) 4.61–4.71 
(m, 2 H, Hb-1 and H-2”) 5.21–5.30 (m, 1 H, H-2) 5.57 (d, J = 3.9 Hz, 1 H, H-1”) 5.93 (br. s, 6 H, OH) 7.19–7.30 (m, 
3 H, arom. H) 7.30–7.38 (m, 2 H, arom. H) 8.27 (t, J = 5.6 Hz, 1 H, (CO)NH) 8.47 (d, J = 8.6 Hz, 1 H, NH(CO)).
13C NMR (75 MHz, pyridine-d5) δ 14.69, 23.35, 23.47, 26.77, 27.59, 29.60, 30.02, 30.15, 30.18, 30.25, 30.34, 
30.40, 30.57, 32.11, 32.52, 34.43, 36.43, 37.18, 37.34, 40.06, 51.77, 63.07, 68.99, 70.70, 71.40, 71.98, 72.64, 73.46, 
77.25, 101.95, 126.43, 129.10, 129.24, 143.53, 173.61, 173.68.
Exact mass (ESI-MS) for C42H75N2O10 [M + H]+ found, 767.5412; Calcd., 767.5416; m.p. 148–150 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-nonadecanamino-N-(6-phenylhexyl)octanamide 
(8d). 1H-NMR (300 MHz, pyridine-d5) δ 0.88 (t, J = 6.6 Hz, 3 H, terminal CH3) 1.14–1.40 (m, 36 H, CH2) 1.45–
1.61 (m, 4 H, CH2) 1.70–1.88 (m, 2 H, CH2) 1.90–2.05 (m, 1 H, CH2) 2.18–2.58 (m, 9 H, CH2) 3.44 (q, J = 6.7 Hz, 
2 H, NHCH2) 4.23–4.54 (m, 7 H, Ha-1, H-3, H-4, H-4”, H-5” and CH2-6”) 4.57 (d, J = 3.1 Hz, 1 H, H-3”) 4.61–4.72 
(m, 2 H, Hb-1 and H-2”) 5.21–5.31 (m, 1 H, H-2) 5.57 (d, J = 3.8 Hz, 1 H, H-1”) 5.83 (br. s, 6 H, OH) 7.20–7.27 (m, 
3 H, arom. H) 7.31–7.38 (m, 2 H, arom. H) 8.28 (t, J = 5.6 Hz, 1 H, (CO)NH) 8.49 (d, J = 9.0 Hz, 1 H, NH(CO)).
13C NMR (75 MHz, pyridine-d5) δ 14.69, 23.35, 23.47, 26.78, 27.61, 29.62, 30.02, 30.20, 30.26, 30.32, 30.43, 
30.55, 32.11, 32.52, 34.41, 36.43, 37.19, 37.34, 40.08, 51.77, 63.07, 68.96, 70.68, 71.40, 71.97, 72.64, 73.45, 77.22, 
101.93, 126.43, 129.10, 129.24, 143.53, 173.66, 173.71.
Exact mass (ESI-MS) for C46H83N2O10 [M + H]+ found, 823.6036; Calcd., 823.6042; m.p. 136–138 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-hexacosylamino-N-(6-phenylhexyl)octanamide 
(9d). 1H-NMR (300 MHz, pyridine-d5) δ 0.88 (t, J = 6.4 Hz, 3 H, terminal CH3) 1.11–1.43 (m, 42 H, CH2) 1.43–
1.62 (m, 6 H, CH2) 1.81 (quint, J = 7.3 Hz, 2 H, CH2) 1.91–2.07 (m, 2 H, CH2) 2.12–2.30 (m, 2 H, CH2) 2.34–2.61 
(m, 8 H, CH2) 3.03 (q, J = 7.4 Hz, 2 H, CH2) 3.43 (q, J = 6.6 Hz, 2 H, NHCH2) 4.26–4.45 (m, 6 H, Ha-1, H-3, H-4, 
H-4” and CH2-6”) 4.49 (q, J = 5.9 Hz, 1 H, H-5”) 4.56 (d, J = 2.9 Hz, 1 H, H-3”) 4.60–4.70 (m, 2 H, Hb-1 and H-2”) 
5.19–5.30 (m, 1 H, H-2) 5.57 (d, J = 3.8 Hz, 1 H, H-1”) 6.33 (br. s, 6 H, OH) 7.17–7.27 (m, 3 H, arom. H) 7.30–7.39 
(m, 2 H, arom. H) 8.29 (t, J = 5.4 Hz, 1 H, (CO)NH) 8.49 (d, J = 8.5 Hz, 1 H, NH(CO)).
13C NMR (75 MHz, pyridine-d5) δ 8.89, 14.66, 23.32, 23.45, 26.75, 27.57, 29.59, 29.99, 30.14, 30.17, 30.25, 
30.29, 30.37, 30.41, 30.52, 32.08, 32.49, 34.37, 36.40, 37.15, 37.31, 40.05, 46.15, 51.78, 63.00, 68.91, 70.67, 71.32, 
71.95, 72.55, 73.40, 77.17, 101.87, 126.40, 129.07, 129.21, 143.50, 173.66, 173.69.
Exact mass (ESI-MS) for C52H95N2O10 [M + H]+ found, 907.6976; Calcd., 907.6981; m.p. 116–118 °C.
(5R,6S,7S)-5,6-dihydroxy-8-O-(α-D-galactopyranosyl)-7-hexacosylamino-N-(3-pentylphenyl)octanamide 
(9f). 1H-NMR (300 MHz, pyridine-d5) δ 0.80 (t, J = 6.9 Hz, 3 H, terminal CH3) 0.88 (t, J = 6.5 Hz, 3 H, termi-
nal CH3) 1.14–1.47 (m, 48 H, CH2) 1.47–1.64 (m, 2 H, CH2) 1.74–1.89 (m, 2 H, CH2) 1.89–2.16 (m, 1 H, CH2) 
2.16–2.33 (m, 1 H, CH2) 2.33–2.51 (m, 4 H, CH2) 2.51–2.60 (m, 2 H, CH2) 2.60–2.74 (m, 2 H, CH2) 4.23–4.46 (m, 
6 H, Ha-1, H-3”, H-4, H-4” and CH2-6”) 4.46–4.53 (m, 1 H, H-3) 4.56 (br. s, 1 H, H-5”) 4.60–4.71 (m, 2 H, Hb-1 
and H-2”) 5.20–5.31 (m, 1 H, H-2) 5.57 (d, J = 3.8 Hz, 1 H, H-1”) 6.27 (d, J = 6.1 Hz, 1 H, OH) 6.32 (d, J = 3.7 Hz, 
1 H, OH) 6.46–6.58 (m, 2 H, OH) 6.72 (br. s, 1 H, OH) 6.97–7.08 (m, 2 H, arom. H and OH) 7.33 (t, J = 7.8 Hz, 
1 H, arom. H) 7.88 (d, J = 7.9 Hz, 1 H, arom. H) 7.97 (s, 1 H, arom. H) 8.46 (d, J = 8.5 Hz, 1 H, NH(CO)) 10.59 (s, 
1 H, (CO)NH).
13C NMR (75 MHz, pyridine-d5) δ 14.54, 14.69, 23.13, 23.35, 23.44, 26.78, 30.02, 30.17, 30.20, 30.26, 30.32, 
30.40, 30.44, 31.80, 32.02, 32.52, 34.35, 36.61, 37.18, 38.24, 51.68, 63.07, 68.87, 70.68, 71.42, 71.98, 72.65, 73.46, 
77.22, 101.88, 117.91, 120.55, 124.11, 129.45, 141.05, 144.26, 172.71, 173.68.
Exact mass (ESI-MS) for C51H93N2O10 [M + H]+ found, 893.6830; Calcd., 893.6825; m.p. 127–129 °C.
N-((2S,3S,4R)-1-O-(α-D-galactopyranosyl)-3 ,4-dihydroxy-16-phenylhexadecan-2-yl)octana-
mide(23). Compound 23 was synthesized in an analogous way as described in scheme 2 and 3. A Wittig olefi-
nation between 14 and triphenyl(10-decylphenyl)phosphonium bromide was followed by selective reduction of 
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the double bond. The azide moiety on C2 was installed using a Mitsunobu inversion with hydrazoic acid (HN3). 
Next, the primary hydroxyl group was selectively deprotected to give the corresponding acceptor, which was 
glycosylated with trichloroacetimidate donor 11. Staudinger reduction of the azide, followed by amide formation 
with octanoic acid, yielded, after overall deprotection, compound 23.
1H-NMR (300 MHz, pyridine-d5) δ 0.81 (t, J = 6.3 Hz, 3 H, terminal CH3) 1.11–2.01 (m, 32 H, CH2) 2.44 (t, 
J = 7.6 Hz, 2 H, CH2) 2.60 (t, J = 7.6 Hz, 2 H, CH2) 4.31–4.35 (m, 2 H, H-2” and H3) 4.38–4.46 (m, 3 H, Hb1 and 
CH2-6”) 4.47 (m, 1 H, H-4) 4.53 (m, 1 H, H-4”) 4.57 (m, 1 H, H-5”) 4.63–4.72 (m, 2 H, Ha1 and H-3”) 5.24–5.34 
(m, 1 H, H-2) 5.60 (d, J = 3.7 Hz, 1 H, H-1”) 5.94 (br. s, 6 H, OH) 7.22–7.29 (m, 3 H, arom. H) 7.31–7.39 (m, 2 H, 
arom. H) 8.49 (d, J = 8.6 Hz, 1 H, NH).
13C NMR (75 MHz, pyridine-d5) δ 14.23, 22.89, 26.37, 26.50, 29.38, 29.56, 29.66, 29.82, 29.98, 30.01, 30.14, 30.38, 
31.89, 34.42, 36.11, 36.77, 51.64, 62.68, 68.65, 70.30, 71.03, 71.67, 71.71, 72.50, 73.05, 76.72, 101.45, 128.73, 128.88.
Recombinant proteins, SPR studies and crystallography. Soluble mCD1-β2 M protein was expressed and purified 
from insect cells as described41. Glycolipid loading and SPR studies were performed as previously reported27. 
In brief, increasing concentrations of TCR (two-fold dilutions from 500 nM to 15.625 nM) were passed over 
streptavidin immobilized CD1d using a CAP chip on a Biacore T200. A reference substraction included the 
TCR binding response to CD1d to which no lipid has been added. In addition, single cycle kinetics were car-
ried out with 3-fold dilutions of TCR (900nM-11nM), without reference substraction. Running buffer contained 
no detergent in an attempt to not extract these short-acyl chain ligands during the course of the experiment. 
CD1d-ligand-TCR complex formation, purification, crystallization and structure determination was performed 
as reported previously19, 25. Data collection and refinement statistics are shown in Table 2. Structure of mCD1d-
5d and mCD1d-23 have been deposited in the Protein Data Bank (http://www.rcsb.org/) under accession codes 
5TW2 and 5TW5, respectively.
In vivo cytokine secretion assay. Experiments were approved by and conducted according to the guidelines of the 
Ethical Committee of Laboratory Animal Welfare of Ghent University.
The different glycolipids were dissolved in DMSO at a concentration of 1 mg/mL, heated for 20 minutes at 
80 °C and subsequently sonicated for 10 minutes at the same temperature. Next, 11 µL of the prepared solution 
Data collection statistics CD1d-23 CD1d-5d
Space group P212121 P212121
Cell dimension
 a, b, c, (Å) 42.2, 106.2, 106.9 42.2, 107.5, 109.6
 a, b, g (°) 90, 90, 90 90, 90, 90
Resolution range (Å) [outer shell] 45–1.85 [1.92–1.85] 40–1.75 [1.81–1.75]
No. reflections 40,100 51,068
Rmeas (%) 13.3 [97.9] 6.9 [58.1]
Rpim (%) 5.5 [41.3] 3.3 [27.5]
Multiplicity 5.4 [5.2] 4.3 [4.3]
Average I/sI 17.1 [2.5] 35.8 [3.1]
Completeness (%) 95.2 [98.6] 99.7 [100.0]
Refinement statistics
No. atoms 3,435 3,385
 Protein 2,992 2,929
 Ligand (spacer/antigen) 18/46 18/46
 Carbohydrate 56 52
Water 323 340
R/Rfree (%) 21.4/24.3 20.3/22.1
Ramachandran plot (%)
 Favored 97.5 98.3
 Allowed 100 100
R.m.s. deviations
 Bonds (Å) 0.008 0.008
 Angles (°) 1.37 1.33
B-factors (Å2)
 Protein 24.4 31.8
 Spacer/Lipid 40.8/29.4 52.5/60.7
 Carbohydrate 44.7 46.8
 Water 31.0 39.7
Table 2. Data collection and refinement statistics of crystal structures of the CD1d-23 and CD1d-5d complexes.
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was diluted with PBS in order to obtain a 10 µg/mL solution and the resulting solution was again warmed to 80 °C 
for 20 minutes followed by sonication for 10 minutes at this temperature. Then, 500 µL (5 µg) was injected i.p. in 8 
different C57BL/6 mice and blood was collected 4 h (IL-4) and 16 h (IFN-γ) post injection. The levels of IL-4 and 
INF-γ were determined by ELISA (eBioscience). KRN7000 was employed as control.
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